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ABSTRACT 
Each individual breast tumor contains a heterogeneous mix of cancer 
cells. Recent evidence suggests that the cellular heterogeneity inherent to 
breast cancer, which underlies metastasis, resistance to treatment and disease 
recurrence, can be driven by a distinct population of tumor cells referred to as 
cancer stem cells. However, the extracellular cues and intracellular signaling 
pathways that cancer stem cells rely on remain largely unknown. The aim of this 
dissertation was to investigate the functional relevance of tumor cell-derived 
periostin , a secreted extracellular matrix (ECM) molecule, to cancer stem cells 
and determine the pathways activated downstream of periostin through the 
integrin av~3 receptor. The rationale for this work was based on correlative 
evidence that connected periostin and integrin av~3 expression to numerous 
phenotypes associated with cancer stem cells including residence in a cell state 
associated with epithelial-mesenchymal transition (EMT), mammosphere 
formation and expression of the CD44+/CD24- surface phenotype. Multiple 
breast cancer cell lines with knockdown of either periostin or integrin ~3 showed 
viii 
characteristics suggestive of a reduced cancer stem cell population such as 
impaired mammosphere formation and an inability to maintain a subpopulation of 
aldehyde dehydrogenase (ALDH)-positive cancer cells, implying that this 
autocrine/paracrine signaling axis is required to maintain breast cancer stem 
cells. Furthermore, this axis was found to be expressed in a subset of basal-like 
breast cancer cell lines. Additionally, high periostin expression was associated 
with a poor prognosis in patients with estrogen receptor (ER)-negative breast 
cancer. Gene expression analysis revealed that breast cancer cells with 
knockdown of periostin exhibited significant suppression of a distinct cytokine 
network, which includes IL-6 and IL-8, two cytokines that have been linked to the 
regulation of cancer stem cells . In a different cellular context, periostin could 
regulate the transcription of multiple WNT ligands. Thus, periostin serves as a 
critical regulator of the cancer stem cell state and acts through integrin signaling 
to control the production of other secreted factors that can also modulate cancer 
stem cells. These findings suggest that basal-like breast cancers can establish a 
microenvironmental niche supportive of cancer stem cells, which might be 
relevant as a biomarker or therapeutic target. 
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GENERAL BACKGROUND AND LITERATURE REVIEW 
Breast cancer 
Cancer is a staggering public health problem. The American Cancer 
Society expects over 1.6 million new cases of cancer to be diagnosed in 20131. 
In women , the majority of these cases -approximately 232,000 (29%) -will be 
classified as breast cancer1. Nearly 40,000 patients with breast cancer will die 
this year, making it the second leading cause of cancer mortality in women , 
behind only lung cancer1 . Fortunately, the number of newly-diagnosed cases 
has decreased steadily since 2000, largely as a result of a reduction in the 
number of post-menopausal women on hormone replacement therapy, which has 
been strongly linked to the development of breast cancer1·2 . Death rates have 
also decreased in recent years and this has been attributed to improvements in 
screening and early detection with mammography as well as better treatment 
options 1. However, racial disparities in outcomes exist for breast cancer; African-
American women have a lower incidence rate but an increased chance of death 1 . 
While this likely reflects socioeconomic factors and access to health care , there 
also seem to be some biological differences since African-American women are 
more likely to be diagnosed with aggressive cancers3.4 . Additionally , over 64,000 
cases of carcinoma in situ are expected this year1 . These are non-invasive 
neoplasms and likely represent a pre-malignant stage in the progression towards 
invasive breast cancer5 . 
1 
Numerous risk factors have been linked to the development of breast 
carcinomas. The most important factors that increase the risk of breast cancer 
are gender, age and family history, and modifiable factors such as obesity, 
physical inactivity and alcohol consumption are thought to confer risk as well 1 . 
There is also a strong relationship between exposure to reproductive hormones, 
such as estrogen and progesterone, and the development of breast cancer in 
postmenopausal women6 , hence the connection between hormone replacement 
therapy and cancer incidence. There do seem to be inherited factors which 
predispose one to breast cancer because having a relative with a history of 
breast cancer increases risk. But this contribution is somewhat limited as most 
patients diagnosed do not have a close relative with breast cancer, and 
conversely, the majority of women that do have a relative with breast cancer will 
never develop the disease1 . The exception here is individuals who inherent a 
mutant allele of BRCA 1 or BRCA2, two well-characterized breast and ovarian 
cancer-susceptibility genes. Women with these inherited mutations have up to 
an 80% chance of developing breast cancer, but these cases account for only 
5%-10% of all breast cancer diagnoses7 . 
Pathological classification of breast cancer 
Breast cancer arises from malignant transformation of epithelial cells in 
the mammary gland. The normal epithelium of the breast is organized as a 
series of ducts and lobules, designed to secrete milk and transport it to the 
nipple. On the cellular level, luminal epithelial cells line the ducts and , along with 
2 
alveolar cells, are present in the lobules. Myoepithelial cells circumscribe these 
cells and form a basal layer of epithelium, which rests on the basement 
membrane separating the epithelial and connective tissue. The vast majority of 
carcinomas - upwards of 75% to 80% - arise in the ductal region and have the 
histological designation of invasive ductal carcinoma, not otherwise specified 
(IDC NOS)8-10 . The remaining 20% to 25% of cases are referred to as "special 
types" and occupy one of 17 different histological subtypes, each with less than a 
5% overall incidence9 . 
In addition to histological type, which categorizes tumors based on tissue 
morphology, the histological grade of the cancer reflects the degree of cellular 
differentiation as well as the mitotic rate. Histological grade is routinely used to 
classify cases of breast cancer and it serves as a good prognostic indicator, 
where poorly-differentiated and highly-proliferative cancers generally have worse 
clinical outcomes 11 . Breast cancers are also subject to a staging process that 
evaluates the size of the primary tumor, the dissemination to regional lymph 
nodes and the presence or absence of distant metastases. The disease stage is 
an indicator of the extent to which a cancer has spread and it is the most 
important factor in determining the patient's prognosis and treatment options 12 . 
Finally, there are a number of well-characterized molecules that are also 
used to classify, prognosticate and guide treatment decisions. Foremost here is 
the estrogen receptor (ER), a nuclear hormone receptor that, upon binding 
estrogen , translocates to the nucleus and regulates the transcription of numerous 
3 
target genes, many of which are involved in cell proliferation 13 . Roughly 70% of 
breast tumors are classified as ER-positive and the majority of these also 
express the progesterone receptor (PR) , another member of the nuclear receptor 
superfamily that is commonly assessed by pathologists 14 . Hormone receptor 
expression is less of a prognostic factor because it is correlated to histological 
grade15 , however, because the growth of most of these cancers is hormone-
dependent, ER/PR expression is strongly predictive of a response to endocrine 
therapies such as tamoxifen and aromatase inhibitors 16. 
The human epidermal receptor-2 (HER-2 , also known as ERBB2) is an 
oncogenic growth factor receptor that is now included in the standard 
pathological assessment of breast cancers. Up to 30% of cases harbor 
amplifications of this gene 17 that generally result in an increased abundance of 
the protein in the plasma membrane, where it functions to stimulate intracellular 
growth and division signaling pathways. Patients with amplified HER2 have an 
aggressive form of the disease and a substantially worse prognosis 17·18 but with 
the advent of targeted therapies, such as trastuzumab, which specifically targets 
the HER-2 protein , these patients have seen remarkable response rates and a 
corresponding benefit in terms of disease outcome 19 . Today, the HER2 
oncogene serves as a prime example of a patient-tailored molecular target, 
subject to standard pathologic detection and amenable to drug inhibition. 
Another collection of breast tumors , referred to as triple-negative breast 
cancer (TNBC), is defined by the absence of ER, PR and HER-2 expression. 
4 
TNBC accounts for about 15% of all breast cancers, tends to occur in younger 
patients and is associated with poor short-term survival20 . Importantly, these 
patients are not eligible for targeted therapies such as tamoxifen and 
trastuzumab because they do not express ER and HER-2. Despite intense 
study, no clear genetic lesion can be targeted clinically and TNBC remains a 
particularly aggressive malignancy. 
Molecular subtypes of breast cancer 
A major milestone in breast cancer research was reached in 2000 when it 
was reported that breast cancers could be classified into different subgroups 
based on their gene expression profiles21 ·22 . This unprecedented molecular view 
of breast tumors suggested that common transcriptional programs, shared 
between different tumors, could explain some of the biologic variability inherent 
to breast cancer that had been observed by pathologists and oncologists for 
years. Five subtypes were originally described: two luminal subtypes (luminal A 
and luminal B), which are hormone-receptor positive; a HER-2 positive subtype; 
a basal-like group that shares a gene expression profile similar to myoepithelial 
cells of the normal breast and generally lack expression of HER-2 and the 
hormone receptors; and a heterogeneous, "normal-like" collection of tumors. 
These subtypes have been repeatedly observed23 '24 and, importantly, are 
associated with distinct clinical outcomes, where the HER-2 and basal-like 
subtypes have the worst prognosis22 . There is a significant overlap between 
TNBC and the basal-like subtype as most cases of TNBC, but not all, are 
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classified as basal-like , and vice versa25. It is also worth noting that the majority 
of women with mutations in BRCA 1 develop basal-like cance~3 . Recently, an 
additional claudin-low subtype that has reduced expression of tight junction and 
cell-cell adhesion genes has been observed as well26 . These tumors exhibit an 
epithelial-to-mesenchymal (EMT) phenotype, are more resistant to chemotherapy 
and appear to include most cases of metaplastic breast cance~7 . 
The appearance of these intrinsic molecular subtypes may reflect a 
different cell of origin28 , varying driver mutations29 , differences in the 
microenvironment30 or some combination thereof (Figure 1). Regardless, these 
gene expression signatures help to capture and conceptualize the basic 
biological , pathological and clinical differences underlying the heterogeneous 
spectrum of breast cancers that arise in different patients. 
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INTERTUMOR HETEROGENEITY 
•Cell of origin (epigenetic background) 
•Mutational profile 
•Transcriptional networks 
•Microenvironment 
Tumor A Tumor B TumorC 
Differences could include: histological 
type, molecular subtype, driver 
mutations, metastatic t ropism and 
response to chemotherapy. 
Figure 1. lntertumor heterogeneity in breast cancer. lntertumor heterogeneity 
is used to describe the varying characteristics, such as those listed in the box 
below, that exist between tumors arising in different patients. Potential sources 
of this heterogeneity are listed above. 
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lntratumor heterogeneity and the cancer stem cell hypothesis 
It is abundantly clear, as discussed above, that there are considerable 
differences among individual breast tumors - in their cellular origins, pathological 
and molecular classifications, genomic mutations and, importantly, in their 
propensity to metastasize and respond to chemotherapy. However, cancer cells 
within the same tumor are also heterogeneous and exhibit a range of 
phenotypes, an observation referred to as intratumor heterogeneitl1 . This 
added level of complexity presents daunting challenges for both cancer research 
and clinical oncology, so recent efforts have been directed at understanding the 
basis for this heterogeneitl2-34 . 
One model put forth to explain this phenomenon, the clonal evolution 
model , is essentially Darwinian natural selection and posits that the cancer cells 
which acquire the most advantageous set of mutations will be selected for over 
time, and thus, drive disease progression35 '36 . This is perhaps best exemplified 
in the classic "Vogelgram" that established a model to describe the sequential 
mutations acquired during colorectal tumorigenesis37 . Recent genomic studies, 
which compare shared and unique mutations present in the tumor mass, have 
also suggested that a process of clonal evolution occurs in tumors, both spatially 
and temporally. In one example, sequencing of individual breast cancer cells 
from a TNBC revealed three discernable clonal populations which probably 
emerged early during tumorigenesis38 . In another example, whole-genome 
sequencing was used to compare paired tumor and metastatic samples to 
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examine the cellular populations contributing to disease progression. In at least 
one basal-like breast cancer, the metastatic lesion was likely seeded from a 
small subpopulation of cells present in the primary tumor and exhibited relatively 
few new genetic alterations39 . In a larger analysis of 21 breast cancers, whole-
genome sequencing revealed that most of these tumors harbor a dominant 
cellular population, although substantial subclonal differences evolved 
subsequently as most mutations were restricted to only a subset of all tumor 
cells40 . Such genetic studies offer a powerful tool to examine intratumor 
heterogeneity and these early studies offer a fascinating view of the subclonal 
structure present in breast tumors. However, they do not causally link these 
evolutionary processes to tumor heterogeneity, they only describe the structure 
of the heterogeneity that is present. 
The cancer stem cell hypothesis is another model that has been proposed 
to account for the heterogeneity found within tumors41 -43 . This idea was given 
new life in the mid-1990s when it was reported that acute myeloid leukemia 
(AML) is driven by a rare population of leukemia stem cells (marked as 
CD34+/CD38-), apparently generated from mutation of a normal hematopoietic 
stem cell44·45 . The salient implication from this work is that AML is organized as a 
hierarchy since only the leukemia stem cells had the ability to self-renew, 
differentiate into non-stem cancer cells, and initiate the disease when 
transplanted into immunocompromised mice45 . While these studies firmly 
established the cancer stem cell paradigm, they also led to some confusion. The 
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cancer stem cell concept is meant to describe the source and organization of 
intratumor heterogeneity- that is, that the tumor is organized hierarchically- not 
the cell of origin46 .47 . Since then , cancer stem cells have been identified in other 
hematological malignancies such as chronic myeloid leukemia48 , as well as in 
solid tumors, most notably of the breast, brain and colon47·49 , based on their 
enhanced capacity to initiate tumorigenesis. Although this model might not be 
applicable to all cancers50 '51 , in tumors that are arranged hierarchically the 
cancer stem cells assume a particularly important role, where they fuel tumor 
growth , give rise to other types of tumor cells and serve as the seeds of 
metastasis and recurrence52 ·53 . In these cancers, it would seem that any 
efficacious therapeutic regimen would need to target the cancer stem cells54 ·55 . 
This notion is fundamentally different from that of the clonal evolution model , in 
which all cells of the tumor have a similar potential for tumorigenesis and disease 
progression is largely a stochastic process. 
These two concepts (Figure 2) are not mutually exclusive, as even a 
population of cancer stem cells could be subject to the pressures of clonal 
evolution46 ·51 ·53 . But it does seem logical that genetic differences between tumor 
cells would play a prominent role in the clonal evolution model while the 
differences between cancer stem cells and non-cancer stem cells are more likely 
mediated by epigenetic changes47 . 
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Figure 2. lntratumor heterogeneity. lntratumor heterogeneity refers to 
differences between cancer cells within the same monoclonal tumor. In the 
clonal evolution model, cancer cells with a growth or survival advantage are 
selected for over time and due to the accumulation of new genetic mutations 
results in a heterogeneous cellular population. The cancer stem cell model 
predicts that tumors, similar to tissues, are organized as a hierarchy in which only 
the cancer stem cells are tumorigenic. Cancer stem cells can self-renew and 
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generate the various other cancer cell types. Note, that although these two 
models are depicted separately for conceptual purposes, they are not mutually 
exclusive. 
The tumor microenvironment can influence cancer development 
Oncogenesis , undoubtedly, is largely the result of cell-autonomous 
changes such as genetic mutations56 ·57 and epigenetic alterations58·59 , which 
eventually lead to the acquisition of the six hallmarks of cancer: sustained 
proliferative signaling, evasion of anti-growth signals, resistance to apoptosis , 
cellular immortality, angiogenesis and invasion/metastasis60 ·61. However, the 
surrounding stromal cells , of what has been termed the tumor microenvironment, 
also exert a profound effect on the initiation and progression of cancers61-64 . 
Various subtypes of infiltrating immune cells65 , cancer-associated fibroblasts 
(CAFs)66 , and vascular cells67 are either actively recruited by the tumor or arrive 
in response to the growing neoplasm. These diverse cell types act to module 
tumor development through heterotypic signaling with the cancer cells61 . Early 
neoplastic cells are likely restrained by the surrounding normal stroma68 , but as 
tumors progress they are able to manipulate this microenvironment to suit their 
own needs. One example of this involves tumor production of chemokines , such 
monocyte chemoattractant protein (MCP-1 ), which can stimulate the infiltration of 
tumor-associated macrophages (TAMs); TAMs then secrete vascular endothelial 
growth factor (VEGF) to promote angiogenesis69 . Such interactions are 
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pervasive70 and likely influence most, if not all, of the hallmark capabilities shared 
by cancer cells64 . 
In addition to stromal cells, the tumor microenvironment also consists of 
extracellular matrix (ECM) , which is secreted locally by resident cells in the tissue 
or tumor. Broadly, two types of ECM are recognized: the interstitial matrix which, 
occupies the space between intervening cells in the tissue and the basement 
membrane, made largely of collagen type IV, that forms the basal surface on 
which epithelial cells rest62 . The ECM is comprised mainly of fibrous proteins and 
proteoglycans71 ·72 , and can influence the surrounding cells in at least four ways. 
First, the ECM is well known to play a structural role, providing physical support 
and scaffolding for cell adhesion62 . Second, the ECM can directly initiate 
downstream signaling through activation of heterodimeric transmembrane 
integrin receptors73 . Third, ECM proteins are able to bind soluble growth factors , 
enhancing or sequestering their bioavailabilitl4 . Finally, the ECM composition 
can alter the mechanical properties of the interstitial matrix, which can have 
surprisingly profound effects on various biological functions relevant to cancer 
such as proliferation, migration and differentiation74-77 . 
Dramatic changes to the ECM are characteristic during cancer 
progression and it can both restrain and promote neoplastic disease, depending 
on the specific context and components of the matrix. The basement membrane 
clearly counteracts the development of cancer since to progress an epithelial 
tumor must breach the basement membrane and invade the underlying stroma78 . 
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The ECM is also a crucial regulator of normal tissue morphology and cellular 
polarity in the mammary gland79·80. But invasive cancers are often desmoplastic, 
containing large numbers of CAFs, which results in tumor fibrosis with enhanced 
production of ECM proteins such as collagens, fibronectins and 
proteoglycans66·81 . ECM proteins also play a central role in cancer cell migration 
and invasion by activating intracellular signals downstream of integrin receptors, 
most notably focal adhesion kinase (FAK) and small GTPases such as RhoA82 . 
Matrix metalloproteinases (MMPs) , proteolytic enzymes that cleave various 
components of the ECM, are present in the tumor microenvironment and can 
modulate the structure and activity of the matrix to alter tumor progression83-85 . 
For example, both MMP-2 and MMP-9 can process collagen in such a way that 
promotes angiogenesis86·87 . And in recent years, as the process of metastatic 
colonization has begun to be revealed88·89 , ECM proteins have been shown to 
function in this final stage of tumor cell dissemination . Interestingly, a 
premetastatic niche may be formed prior to the arrival of disseminated cancer 
cells90 . In breast cancer this niche seems to be dependent on increased 
expression of fibronectin by resident fibroblasts91 and modulation of collagen to 
induce the recruitment of bone marrow-derived cells (BMDCs) and disseminated 
cancer cells92 . Finally, it is important to note that the matrix is an essential 
aspect of the supportive niche for both normal and cancer stem cells74·76 ·93-97 . 
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Periostin is a component of the extracellular matrix 
The periostin gene, POSTN (also known as osteoblast-specific factor 2, 
OSF-2) , is located on chromosome 13q13.3, contains 23 exons, and encodes a 
secreted ECM protein of up to 836 amino acids, with a molecular weight of 
approximately 90 kDa. The gene was cloned in 1993 from a murine osteoblastic 
cell line, MC3T3-E1, and was noted to share extensive homology to fasciclin I, an 
adhesion molecule important for axonal guidance in Drosophila melanogaster8-
100 In humans, the other three members of the fasciclin family include 
transforming growth factor, beta-induced (TGFBI) , stabilin I (STAB1) and stabilin 
11 (STAB2)100•101. These proteins all have multiple FAS1 domains- named for 
their homology with fasciclin I - and each is comprised of around 150 amino 
acids, that appear to be important for cell adhesion and contain y-carboxylase 
recognition sites 100-102. Four periostin isoforms are currently validated and these 
represent alternatively-spliced transcripts containing different combinations of 
cassette exons (exons 17-21) in the C-terminal region 100·103-105. Although the 
precise function of these different splice variants is not known , an interesting 
cross-species comparison of the POSTN gene in vertebrates indicated that the 
C-terminal region evolved with considerably more plasticity than the rest of the 
gene, which suggests this region might harbor functions novel to periostin 103, 
perhaps relating to interactions with other ECM proteins such as collagen 106 , 
fibronectin 107, heparin 108 and tenascin-C109 . Other important characteristics of 
the protein include a typical N-terminal signal sequence common to secreted 
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proteins, a cysteine-rich EMI domain important for oligomerization of ECM 
proteins110·11 1, two aspartate-isoleucine (01) dimers similar in function to the 
arginine-glycine-aspartate (RGO) motif involved in binding integrins 112 and an N-
glycosylation site 103 . Consistent with the presence of the RGO-Iike 01 motif3 , 
periostin is known to act as a ligand for the following integrin receptors: av~3. 
av~s. a6~4 and some ~1 containing complexes 100 '105 '113 . The major biochemical 
domains of periostin are summarized in Figure 3. 
55 EMI FA51 FA511 FAS1 F.:-511 C-tenninal region 
Figure 3. Periostin structure. Notable biochemical features of POSTN 
are depicted schematically. Full length POSTN is 836 amino acids long with an 
N-terminal signal sequence (SS) for secretion, a cysteine-rich oligomerization 
domain (EM I) and four fasciclin I adhesion domains (FAS1 ). The C-terminal 
region is subject to alternative splicing that defines the four different periostin 
isoforms. The black bars in the second and fourth FAS1 domain specify 
aspartate-isoleucine (01) integrin binding sites. The black triangle in the fourth 
FAS1 domain indicates an N-glycosylation site. This figure is adapted from 
reference 1 03. 
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Periostin is expressed widely in embryonic tissues including the 
periosteum, cardiac valves , placenta, peripheral nervous system and developing 
teeth , where it seems to mark cells that have undergone an epithelial-
mesenchymal transition (EMT) 114-117 . In adult tissues, periostin exhibits a more 
restricted connective tissue expression pattern and remains expressed in the 
periosteum and periodontal ligaments 104 as well as in the valves of the heart114 . 
Recent work has also indicated that periostin may be expressed locally in various 
stem cell niches including the terminal ductal lobular end unit (TDLU) of the 
breast, the intestinal crypt and the area surrounding the bulge stem cells of skin 
follicles118 . Furthermore, periostin expression can be induced in response to 
cutaneous wound repair119-121 , the Th2-type cytokines interleukin-4 (IL-4) and 
interleukin-13 (IL-13)107'122 , and in response to mechanical stimuli123·124 . Based 
in part on this expression pattern (along with its functional roles discussed below) 
periostin has been proposed to be a member of the matricellular family of ECM 
proteins 123·125 . Matricellular proteins function as key modulators of cell-matrix 
interactions because they can bind to cells, through integrin receptors, as well as 
to soluble growth factors , cytokines and other structural ECM proteins 126 ·127 . This 
class of molecules- including proteins such as osteopontin, secreted protein rich 
in cysteine (SPARC), thrombospondin-1 and 2, and tenascin-C- are expressed 
highly during development but in the adult their expression is generally induced 
in response to tissue injury128·129 . 
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Functional roles of periostin 
In attempts to understand the normal function of periostin , multiple mouse 
models with knockout of the gene have been generated. The first such model , 
reported in 2005, was a periostin1acz knock-in mouse in which the /acZ cassette 
was inserted in place of the first exon 117. Mice both heterozygous and 
homozygous for the targeted allele were viable and grossly normal at birth and 
as neonates, consistent with the phenotypes observed for other matricellular 
proteins 128 . However, in periostin-null animals there was a slight increase in 
postnatal lethality and by four months those animals surviving (86%) exhibited 
dwarfism and modest skeletal defects, which may be related to nutritional status 
since these mice have incisor enamel defects and periodontal-like disease that 
may impair their ability to eat properli 17. Another periostin knockout model 
(without the /acZ cassette) revealed that periostin was required for the proper 
eruption of incisors in the mouse, where it was found to localize to the shear 
zone and interact closely with collagen fibrils 130 . Subsequent studies, following 
up on these initial observations, have added further details to the current 
understanding of how, when, and where periostin functions. 
For instance, although knockout of periostin does not alter the 
development of cardiomyocytes, periostin has been found to be induced upon 
acute myocardial infarction (MI) and is required to recruit fibroblasts, properly 
form collagen fibrils and stiffen the ECM, which collectively acts to prevent 
cardiac rupture, leading to enhanced cardiac healing and better survival after 
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Ml 131 . Similarly, in a separate model , mice lacking periostin exhibited alterations 
in cardiac hypertrophy, fibrosis and ventricular remodeling after myocardial 
infarction or long-term pressure overload132 . Additional developmental studies of 
the atrioventricular (AV) values in the chick heart have shown that periostin is 
important for the differentiation of cushion mesenchymal cells to fibroblasts 133·134 
and further examination of periostin-null mice revealed that these animals have 
leaflet defects and valve disease 135 . Moreover, periostin appears to direct 
progenitor cells away from the myocardial lineage in the developing 
heart125 ·136 ·137 . Quite interestingly, in the adult heart, periostin has been reported 
to stimulate the cycling of differentiated cardiomyocytes, which is dependent on 
activation of integrins av, 131 , 133 and 135 as well as downstream activation of the 
phosphatidylinositoi-3-0H kinase (P13K) pathwai 38 . Here too, periostin was 
found to mitigate heart failure after Ml, which has prompted early pre-clinical 
studies to examine the prospect of using periostin , or periostin-derivatives, as 
therapeutic agents to treat myocardial damage 139-141 . 
Periostin also plays functional roles in osseous tissue142 . In osteoblasts, 
periostin promotes osteoblastic adhesion, proliferation , differentiation and 
survival104 ·143 ·144 . The expression of periostin is up-regulated in response to 
mechanical stimuli , such as moderate activity and pressure, which appears to 
suppress the expression of sclerostin (Sost) , an inhibitor of the Wnt signaling 
pathwai 45·146 , to promote anabolic bone metabolism 124 '147 . Furthermore, the y-
carboxylase recognition sites of periostin may have important functional roles in 
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the regulation of bone mineralization 142 '148 . Finally, periostin is suspected to play 
a role in the biological response to fractures as the expression of periostin is 
strongly induced in the days following a fracture 149 . 
As a prototypical matricellular protein, periostin is capable of regulating the 
organization of other ECM proteins, most notably collagen. Periostin is present 
in many collagen-rich connective tissues and co-localizes with collagen la1 150 . 
Interestingly, periostin was able to activate lysyl oxidase (LOX) via an interaction 
with bone morphogenetic protein-1 (BM P-1) , which led to proteolytic activation of 
LOX and subsequent cross-linking of collagen fibrils 151 . Periostin can directly 
interact with fibronectin and tenascin-C109 and this may generate a functionally 
important ECM architecture, especially in the context of bone formation , where 
most of these interactions have been studied152 . Periostin can also alter the 
surrounding ECM, and perhaps collagen fibril formation as well153 , by enhancing 
the secretion of MMP-2, MMP-9 and MMP-13154·155 . Furthermore, an association 
between periostin and laminin has been reported recently and this interaction 
was necessary for the proper proliferation of keratinocytes during wound 
healing 119. In addition to the specific interactions noted above, periostin also has 
been demonstrated to physically interact with Notch1, which might increase Bcl-
xL levels to prevent cell death 156 . 
Apart from the well-studied function of periostin in the bone 142 and 
heart137 , recent work has begun to reveal a role for periostin in chronic 
inflammatory conditions and the resulting fibrotic response that often 
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accompanies such diseases 157 . In asthmatic patients, periostin expression in the 
airway epithelium was significantly increased relative to normal subjects 158 ; 
subsequently, IL-13- a Th2-derived cytokine linked to bronchial asthma 159 - was 
found to induce periostin expression in human epithelial bronchial cells 160 . In this 
model system, overexpression of periostin resulted in increased transcription of 
TGF-13 ligands, which was dependent on the induction of MMP-2 and MMP-9160 . 
Through this signaling pathway periostin was able to drive enhanced secretion of 
type 1 collagen , as well as increased cross-linking of collagen fibrils, implying 
that periostin can promote airway fibrosis in asthma 160 . Similar observations 
have been made in a genetically-engineered mouse model of the allergic 
inflammatory skin disease atopic dermatitis 161 , although the mechanism of 
periostin action was slightly different. Here, periostin expression was found to 
induce the proliferation of keratinocytes and skin inflammation downstream of 
integrin av161 . Periostin was also able to activate NF-KB signaling in 
keratinocytes to stimulate the production of various Th2 cytokines including 
thymic stromallymphopoietin (TSLP) , and perhaps tumor necrosis factor-a (TNF-
a), granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-
1 alpha (IL-1 a), which all required the presence of periostin to fully induce their 
expression upon treatment with IL-13161 . This places periostin as a central link in 
a so-called "viscous circle in allergic skin inflammation 161 ." Finally, periostin 
expression has been noted to be increased in dystrophic muscle tissue 162 , 
another disease characterized by increased inflammation and fibrosis 163 . In a 
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genetically-engineered model of muscular dystrophy, loss of periostin improved 
muscle function and regeneration , ostensibly by modifying cellular responses to 
TGF-13 signaling 163 . 
Periostin and cancer 
Periostin function has been most extensively studied in the context of 
cancer. Periostin is overexpressed in numerous cancer types and , in general , an 
oncogenic role has been ascribed to this ECM protein 100 . Initial studies were 
mostly correlative and found that high periostin expression was associated with a 
poor prognosis in non-small cell lung cancer164 , thymoma 165 and 
neuroblastoma 166 . Early mechanistic studies revealed that epithelial ovarian 
carcinoma cells secreted periostin , which led to the inclusion of integrins avl33 and 
avl35 in focal adhesion plaques and enhanced cell motility1 67 thus, for the first 
time, highlighting a potential functional role for periostin in the malignant 
progression of cancer. This notion was expanded on in a comprehensive study 
examining the molecular mechanisms of periostin action in colon cancer cells , 
where periostin was highly expressed in 80% of human colon cancers and where 
high expression was associated with metastatic disease 168 . Ectopic expression 
of periostin in human colon cancer cells led to an increase in the number of 
metastatic lesions formed in liver when these cells were injected 
intrasplenically168 . Interestingly, the data suggested that periostin can act on 
both vascular cells as well as cancer cells ; it prevented apoptosis in endothelial 
cells, which was linked to the enhanced angiogenesis observed in experimentally 
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induced metastases, and it could activate the AKT/protein kinase B (PKB) 
survival pathway downstream of integrin av~3 in tumor cells 168 . This study was 
the first to report a pro-survival function of periostin in the context of cancer and 
the first to examine, in any detail , the intracellular signaling pathways activated 
downstream of periostin in cancer cells , signals which appeared to be particularly 
beneficial to nascent metastatic cells colonizing a new tissue environment. 
Additional studies have suggested that periostin can also act to facilitate 
tumor cell invasion in head and neck squamous cell carcinoma (HNSCC)169 , oral 
squamous cell carcinoma (OSCC)170 , esophageal squamous cell carcinoma 
(ESCC) 171 , and pancreatic ductal adenocarcinoma (PDAC) 172 . In ESCC, 
periostin is represented in a gene expression signature of tumor invasion derived 
from transformed esophageal cells expressing telomerase reverse transcriptase 
(hTERT), epidermal growth factor receptor (EGFR) and mutant p53, and in these 
cells periostin expression depends on the presence of constitutively-active EGFR 
as well as mutated p53171 . Gain and loss of function experiments both indicated 
a role for periostin in cancer cell migration and invasion but the underlying 
mechanism for this was not identified171 . High periostin expression was 
observed in human PDAC samples and cell line studies demonstrated that 
integrin a6~4 could act as a receptor for periostin, which activated P13K, FAK and 
AKT/PKB172 . In line with earlier reports in other cancers , periostin-mediated 
activation of this signaling pathway was found to be important for tumor cell 
invasion and survival under hypoxic conditions 172 . A similar signaling pathway 
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involving integrin as~1 has been reported to be relevant for the invasion of 
cholangiocarcinoma cell invasion 173 . Periostin can also stimulate activation of 
the MAPK pathway in pancreatic cancer cells 174 . 
Periostin is highly expressed in non-small cell lung cancer (NSCLC)175 and 
it is correlated with lymphangiogenesis, angiogenesis and pathological markers 
of tumor progression , suggesting that periostin could serve as a useful prognostic 
biomarker176·177. In the A549 lung cancer cell line, periostin expression was 
induced in response to hypoxia and enhanced cell survival via activation of 
AKT/PKB178; in separate studies using this same cell line, periostin was noted to 
promote cell proliferation and migration 179. Tumors isolated from patients with 
gastric180·181 and prostate182·183 cancer exhibit increased periostin expression and 
early studies suggest that it may function to promote cell survival and 
angiogenesis 181 ·184 , although the relevant signaling pathways are not yet clear. 
It should be noted that in bladder cancer, periostin was reported to be 
down-regulated185 . In this context periostin has been found to counteract cell 
invasion 186 , although these differences may be explained by isoform-specific 
expression differences 187. However, in the vast majority of studies periostin has 
been found to play an oncogenic role , influencing nearly every hallmark of 
cancer100 , with the exception , perhaps, of cell immortalization. 
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Periostin and breast cancer 
Periostin was first linked to breast cancer in 2003, when it was reported 
that patients with elevated serum levels of periostin were more likely to present 
with bone metastasis 177 . Although periostin levels were also elevated in the 
serum of patients with small cell lung cancer, this was not associated with 
metastasis to the bone suggesting that periostin could be a biomarker specific for 
breast cancers with metastatic bone involvement1 77 . Numerous other studies 
have found that, relative to normal breast tissue, periostin is highly expressed in 
breast cancer188-193. Interestingly, high periostin expression has been reported to 
be associated with triple-negative cancers 193 , which is consistent with the 
observation that a mutant BRCA 1 protein can lead to the up-regulation of 
periostin expression 194 , since most BRCA 1 carriers develop triple-negative 
disease23. In tumors , periostin is altered mainly at the level of gene expression , 
and it can be derived from the carcinoma cells or the surrounding stromal 
cells 195 . However, one study did uncover a single nucleotide polymorphism in 
the periostin gene associated with high grade, ER-negative cancer196 . 
The known functional roles of periostin in breast cancer are somewhat 
limited but it does seem to impact tumor growth and progression in a variety of 
ways. First, periostin has been found to promote the growth of xenograft tumors, 
ostensibly by enhancing angiogenesis 197 . On the molecular level , periostin was 
able to activate the integrin avr33-FAK pathway in cultured endothelial cells , which 
led the induction of FLK-1/KDR expression , a receptor for vascular endothelial 
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growth factor197. Further support for the relevance of this mechanism derives 
from the fact that injection of monoclonal antibody (OC-20) that disrupts the 
interaction between periostin and integrins avf33 and avf3s was able to significantly 
reduce tumor growth 198. Periostin signaling through integrin avf35 has also been 
linked to the induction of EMT105'199, a process known to play a key role in the 
malignant progression of tumors200-202 , implying that periostin might also play 
important roles in the steps leading to the dissemination and metastatic 
outgrowth of breast cancer cells. Some preclinical data suggests this may true 
as inhibiting periostin with either a neutralizing antibody2°3 or DNA aptame~04 
was able to impede the metastatic growth of the murine 4T1 breast cancer cell 
line. This may be related to the inhibition of periostin-stimulated FAK and SRC 
activation204 . Recent evidence suggests that periostin is also a key component 
of a microvascular niche that supports the outgrowth of dormant micrometastatic 
breast cancer cells205 . Finally, periostin appears to play a role in the regulation of 
highly-malignant breast cancer stem cells96'206 , a topic addressed in more detail 
in Chapter 1. 
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Specific aims 
It is within this context that the current project was conceived of and 
carried out. We hypothesized that periostin expression is required for the 
maintenance of a cancer stem cell phenotype, which occurs through activation of 
integrin signaling , and sought to test this under the following specific aims: 
Aim 1: Define the functional relevance of periostin expression to breast cancer 
stem cells. 
Aim 2: Identify the pathways regulated by periostin in breast cancer stem cells . 
For the purpose of this dissertation each aim has been divided into a 
separate chapter. 
27 
CHAPTER 1: THE FUNCTIONAL RELEVANCE OF PERIOSTIN EXPRESSION 
TO BREAST CANCER STEM CELLS 
BACKGROUND 
Characteristics of breast cancer stem cells 
The first evidence for the presence of a cancer stem cell subpopulation in 
breast cancer, indeed the first evidence for cancer stem cells in any solid tumor, 
was reported in 2003207 . To differentiate between highly tumorigenic cancer 
stem cells - also referred to as tumor-initiating cells (TICs) - and the non-
tumorigenic bulk population , primary human cancers were engrafted into 
NOD/SCID mice and fractionated with flow cytometry based on the expression of 
multiple cell surface markers207 . Tumorigenic breast cancer cells , capable of 
initiating tumor growth at limiting dilution , with as few as 200 cells , were enriched 
in the population of cancer cells with the combination of CD44+/CD24-110w surface 
phenotype; the percentage of tumor cells expressing this combination of markers 
ranged from 11-35%207 . Perhaps most interesting was the observation that the 
tumors formed from injection of this subpopulation were not uniformly 
CD44+/CD24-110w, but rather recapitulated , to a large extent, the original 
heterogeneity found to exist in the tumor with respect to these markers207 . Taken 
together with the fact that this subpopulation could serially propagate tumors, the 
implication was that cancer cells within this fraction could both self-renew and 
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differentiate into non-tumorigenic cells , suggesting a hierarchy for tumor growth 
and heterogeneity consistent with a cancer stem cell model49·207. 
Since this seminal study, additional markers have been suggested to 
enrich for breast cancer stem cells , such as retention of the dye PKH-26208 , efflux 
of Hoechst 33342209 , and expression of CD133 (also known as prominin-1 )2 10 or 
PROCR (protein C receptor, endothelial)34 . Foremost here has been the 
detoxifying enzyme aldehyde dehydrogenase 1 (ALDH1 )211 , which has been 
found to be highly active in both normal mammary stem/progenitor cells as well 
as breast cancer stem cells212 . ALDH1 was originally discovered to be a marker 
of stem and progenitor cells in the hematopoietic system213-215 , but it can also be 
used to enrich for mammary cells with stem cell properties such as 
mammosphere formation , in vitro self-renewal , multi-lineage differentiation 
potential and in vivo outgrowth of ductal structures upon injection into cleared , 
humanized fat pads of NOD/SCID mice21 2 . Moreover, only ALDH-positive 
primary human breast cancer cells , which represented 3-10% of the total cancer 
cell population , were found to be tumorigenic in a limiting dilution tumorigenesis 
analysis and the resulting tumors that were formed reflected the initial 
heterogeneity in ALDH activity, suggesting that these cells have cancer stem 
cell-like properties2 12 . Interestingly, there was little overlap (1.2%) between 
ALDH-positive cancer cells and those expressing the previously characterized 
CD44+/CD24- surface marker profile; however, this small population was highly 
tumorigenic and could initiate a tumor when as few as 20 cells were injected21 2 . 
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High protein expression of ALDH1 , as assessed by immunohistochemistry (IHC), 
was found to be an independent prognostic factor in breast cancer, associated 
with a higher relative risk of death212 . In addition to identifying a new cancer 
stem cell marker, this study suggested that molecular similarities exist between 
normal mammary stem cells and their malignant counterparts. 
Such similarities also extend to an in vitro method to culture and 
propagate human mammary stem/progenitor cells as what has been termed 
mammospheres216 . When normal human mammary epithelial cells are grown 
under these non-adherent conditions, most cells die but the small surviving 
fraction is highly enriched with stem/progenitor cells , which are able to self-renew 
to generate new mammospheres and are capable of differentiating into all three 
epithelial lineages in the mammary gland- luminal , myoepithelial and alveola~16 . 
This is analogous to similar assays to enrich for neural stem cells that preceded 
the development of mammospheres217 . Interestingly, such sphere-forming cells 
have been identified in primary human breast tumors as well as breast cancer 
cells lines and the cancer cells capable of growth as spheres are predominantly 
CD44+/CD24- and were tumorigenic when injected at limiting dilution218 , 
suggesting that, similar to high ALDH activity, the ability to generate non-
adherent mammospheres is a characteristic shared by both normal and 
cancerous stem-like cells. 
Importantly, such functional heterogeneity has also been found to exist in 
multiple human breast cancer cell lines. One early study that examined seven 
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established breast cancer cell lines (MCF1 OA, MCF7, SUM149, SUM159, 
SUM1315 and MDA-MB-231) found that CD44+/CD24- cells , which were also 
positive for epithelial specific antigen (ESA) , were more tumorigenic (forming 
tumors with only 1 00 cells injected) , preferentially formed mammospheres and 
could self-renew in vitro219. Similarly, many breast cancer cell lines (23 of 33 
examined) - including all of the basal-like cell lines - contain an ALDH-positive 
subpopulation that has an enhanced capacity to generate mammospheres and 
exhibits cancer stem cell traits in vivo220 . These studies indicate that many 
breast cancer cell lines also contain stem-like cancer cells that can be 
prospectively separated , cultured and studied , thereby providing a model to 
investigate their underlying biology. 
EMT and breast cancer stem cells 
In 2008, another characteristic shared by normal and malignant stem cells 
emerged when it was discovered that EMT and the stem cell state were 
intimately linked221 . The evidence for this derived largely from two 
complementary approaches. The first approach was correlative and showed that 
primary mammary stem cells isolated from mouse or human tissue expressed 
markers associated with a mesenchymal phenotype including reduced E-
cadherin expression and increased expression of N-cadherin , vimentin and the 
EMT-inducing transcription factors TWIST1 , SLUG and FOXC2; conversely, cells 
within the CD44+/CD24- fraction displayed mesenchymal features and stem cell 
properties including the ability to generate mammospheres221 . In the second 
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approach, when cells were stimulated to undergo EMT, through either expression 
of EMT-inducing transcription factors or treatment with TGF-131, they acquired 
phenotypes associated with the stem cell state such as a CD44+/CD24- surface 
profile, an enhanced ability to form mammospheres and, in the case of cancer 
cells, the capacity to seed tumors at limiting dilution221 . These findings, along 
with another study published shortly thereafte~22 , provided an intriguing 
connection between a latent developmental program - often activated as 
carcinomas progress to metastatic disease - cellular plasticity, and the formation 
of stem-like cells201 ·223 . Moreover, they pointed to common pathways that may 
regulate normal and malignant stem cells and suggested that molecular effectors 
of the EMT program could be important for the regulation of breast cancer stem 
cells. Indeed, a series of autocrine/paracrine signals involving TGF-13 and the 
WNT pathway have been reported to maintain the mesenchymal and cancer 
stem cell state224 . 
Clinical relevance of breast cancer stem cells 
Given that human cancer stem cells have been defined based on their 
ability to seed tumors in immunocompromised mice, their clinical relevance has 
been a matter of debate. However, multiple studies support the idea that breast 
cancer stem cells are a highly malignant population of cancer cells that seem to 
be resistant to standard chemotherapy. For example, a gene expression 
signature, derived from comparing expression profiles of CD44+/CD24- primary 
breast cancer stem cells with normal breast epithelium, was found to be 
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associated with reduced metastasis-free and overall survival in a cohort of breast 
cancer patients225. One interpretation of this finding is that tumors positive for the 
CD44+/CD24- gene expression signature contain an increased proportion of 
cancer stem cells , which contributes to the aggressive nature of these cases225. 
In a study that examined biopsies before and after neoadjuvant chemotherapy, 
the percentage of CD44+/CD24- tumor cells and the ability of tumor cells to form 
mammospheres was significantly increased, implying that a subpopulation of 
cells exhibiting phenotypes associated with cancer stem cells was able to survive 
and expand during this initial treatment226 . This is in line with the finding that 
cancer cells surviving treatment with either an aromatase inhibitor or 
chemotherapy have a gene expression profile reminiscent of breast cancer stem 
cells, which is characterized by the up-regulation of numerous mesenchymal 
genes227 . Thus, breast cancer stem cells represent an attractive therapeutic 
target and the elimination of such cells may be necessary to combat disease 
recurrence and metastatic colonization55·228-230 . Such an approach has been 
demonstrated in principle231 , but the true contribution of cancer stem cells to 
breast cancer may only be known once clinical trials based on cancer stem cell-
specific therapies have been completed . Meanwhile, the biological mechanisms 
that regulate cancer stem cells have begun to come into focus. 
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Periostin and breast cancer stem cells 
Since normal stem cells rely on a supportive niche, it has long been 
proposed that cancer stem cells may require similar signals from the surrounding 
microenvironment43·232 '233 . The ECM is an important component of this niche234 
and various ECM proteins such as tenascin-C and osteopontin have been 
reported to alter the physiologic regulation of stem cell activity235-237. In early 
2012, a similar layer of detail was added to the ECM interactions that govern 
breast cancer stem cells when it was reported that periostin is an important 
regulator of cancer stem cell maintenance in the context of metastatic 
colonization 118 . 
This study utilized a genetic model of breast cancer, the MMTV-PyMT 
mouse, which can spontaneously progress to metastatic disease and is capable 
of colonizing the lungs over time238 . Using the cell surface markers CD90 and 
CD24, previously used to isolate cancer stem cells in a different model of breast 
cance~39 , a population of metastatic cancer stem cells was identified118 . These 
metastasis-initiating cells were contained within the small fraction of tumor cells 
(less than 4%) that was marked as CD90+/CD24+, had a significantly higher 
proliferation rate after initial colonization of the lung , and generated metastases 
with the same frequency of cancer stem cells as the primary tumor118 . 
Interestingly, the expression of periostin in lung fibroblasts was induced in 
response to TGF-132 and TGF-133, and CD90+/CD24+ cancer stem cells were 
found to localize in contact with the surrounding stromal cells 118 . When MMTV-
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PyMT mice were crossed with periostin knockout mice, there was a significant 
decrease in ability of the tumor cells to colonize the lung; however periostin-
deficient tumor cells could still initiate metastases in wild-type animals , indicating 
that stromal-derived periostin was key to the metastatic growth of these cells 118 . 
This phenotype was linked to the ability of periostin to promote the proliferation 
and maintenance of the cancer stem cell population 11 8 . Mechanistically, periostin 
was found to interact with the ligands Wnt1 and Wnt3A, which led to enhanced 
activation of the Wnt signaling pathway; activation of Wnt signaling , in vitro and in 
vivo, can rescue a deficiency in periostin, implying that this represents the major 
mode of periostin action in this model of breast cancer11 8 . This is consistent with 
the role of Wnt signaling in the regulation of normal and malignant stem cells240 . 
Moreover, these findings are remarkably similar to studies of tenascin-C , a 
protein that interacts with periostin 109 , which found this ECM protein was also 
required to maintain metastasis-initiating cells through modulation of the Wnt and 
Notch signaling pathways96 ·206 '241 . However, tenascin-C was produced from both 
stromal and tumor cells241, suggesting that some breast cancer cells may be able 
to secrete their own niche. 
In this chapter we considered the possibility that tumor cell-derived 
periostin was required for the maintenance of breast cancer stem cells . 
Furthermore, we investigated whether integrin receptors for periostin could play a 
role in this process. 
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MATERIALS AND METHODS 
Cell culture 
All M cell lines (MI , Mil , Mill , Mill pB, Mill pB-SMAD7, Mill shGFP, Mill 
shSMAD2 and Mill shPN) were cultured in DMEM F/12 media containing 5% 
horse serum, 10 IJg/ml insulin , 20 ng/ml EGF, 0.1 ng/ml cholera toxin and 0.5 
IJg/ml hydrocortisone. SUM159 (shGFP, shPN and shBeta3) and SUM149 cell 
lines were cultured in Ham's F/12 supplemented with 5% FBS, 10 IJg/ml insulin 
and 0.5 IJg/ml hydrocortisone. The MDA-MB-453, UACC812, Hs578T and MDA-
MB-468 lines were maintained in DMEM containing 10% FBS. T47D and BT549 
cells were cultured and RPM I containing 10% FBS and the SUM1315 line was 
cultured in Ham's F/12 supplemented with 10 IJg/ml insulin and 20 ng/ml EGF. 
All cells were grown in media containing 1% penicillin/streptomycin and 
maintained at 3rC in a humidified incubator with 5% C02. Each cell line was 
screened for mycoplasma with a PCR-based detection kit (Sigma-Aldrich) . 
Mammosphere formation assay 
Cells were trypsinized , resuspended in human MammoCult base media 
(Stem Cell Technologies) and the number of viable cells determined by trypan 
blue exclusion . Five thousand viable cells were seeded in ultra-low attachment 
plates (Corning) in MammoCult media containing the proliferation supplement as 
well as 0.48 IJg/ml hydrocortisone and 1% methylcellulose. Mammospheres 
were incubated at 3rC in a humidified incubator with 5% C02 and allowed to 
grow for 7-10 days. To quantify the number of mammospheres formed, each 
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well was collected, centrifuged at 250xg and resuspended in 500 1-JL of 
MammoCult base media. The number of spheres (over 50 1-JM) in 50 1-JL was 
counted and multiplied by 10 to determine the total number of spheres 
generated. The values presented are normalized to the number of spheres 
formed per 1 000 cells seeded. 
Antibodies and reagents 
The following antibodies were used: periostin (BioVendor) , SMAD7 (Santa 
Cruz Biotechnology) , SMAD2 (Cell Signaling Technology) , CD44-APC and 
CD24-PE (BD Biosciences) , biotinylated anti-integrin avl33 (LM609, Millipore) , 
CD61-PE and streptavadin-PE-Cy7 (eBioscience). TGF-131 (R&D Systems) was 
reconstituted in 4 mM HCI containing 0.1% BSA and cells were exposed to a final 
concentration of 10 ng/ml for 24 hours. 
Flow cytometry 
For examination of cell surface proteins, cells were trypsinized , washed in 
FACS buffer (PBS with 0.2% BSA, 0.09% sodium azide and 1 mM EDTA) and 
stained with antibody for 30 minutes at 4°C. To quantify the percentage of 
ALDH-positive cells , the ALDEFLUOR assay was used (Stem Cell 
Technologies). Briefly, cells were grown in serum-reduced media (0.1% serum) 
for 48 hours, trypsinized , suspended in assay buffer and treated for 30 minutes 
with the ALDEFLUOR reagent (BODIPY-aminoacetaldehyde, BAAA; 3 1-JM) , in 
the presence or absence of the ALDH inhibitor diethylaminobenzaldehyde 
(DEAB; 37.5 1-JM). Propidium iodide (PI)-positive cells were excluded from the 
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analysis. Samples were analyzed on FACScan, FACSCalibur, LSR II or Accuri 
C6 (BD) cytometers. For sorting experiments, cells were washed using a 
different buffer (PBS, 2% horse serum, 1 mM ETDA) and sorted with a MoFio 
(Beckman Coulter). Flow cytometry data was analyzed with FlowJo (Tree Star). 
Quantitative reverse transcription-PeR 
Total RNA was isolated with Trizol (Life Technologies) and eDNA 
synthesized using random primers and SuperScript II Reverse Transcriptase 
(Life Technologies) . Quantitative RT-PCR was performed with Power SYBR 
Green PCR Master Mix (Life Technologies) and run on an Applied Biosystems 
7900HT Sequence Detection System. Relative RNA expression was calculated 
using the MCt method and normalized to beta-actin . The following primers were 
used : 
POSTN, forward 5' - TACAACGGGCAAATACTGGA - 3', reverse 5' -
CTTGATGATCTCGCGGAATA- 3'; 
/TGB3, forward 5' - GATGCGAAAGCTCACCAGTA - 3', reverse 5' -
GCAAGCAGGTGGTCTTCATA- 3'; 
ACTB, forward 5' - CGAGCACAGAGCCTCGCCTTTGCC - 3', reverse 5' -
TGTCGACGACGAGCGCGGCGATAT- 3'. 
The following real time PCR program was used : 50°C, 2 min ; 95°C, 12 min ; cycle 
40x 95°C 20 sec, 5rC 1 min , 72°C 15 sec; 72°C, 10 min . 
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Western blot analysis 
To detect secreted periostin , 1 million cells were cultured in serum-
reduced media (0.1% serum) for 24 hours and the conditioned media 
concentrated using Amicon centriguation filters (30K membrane, Millipore). The 
concentrated protein was mixed with 4x Laemmli 's reducing buffer (Boston 
Bioproducts) , boiled, separated by SDS-PAGE and immobilized on PVDF 
membranes. Secondary antibodies were conjugated to peroxidase and detected 
by chemiluminescence with ECL solution (Perkin-Elmer) . Ponceau staining of 
the membrane was used to show protein loading . 
Generation of knockdown cell lines 
Knockdown cell lines were created by stable expression of shRNAs 
expressed from pLKO-puro.1 lentiviral vectors242 . The 21 base pair sequences 
were designed using the online tools available on the Invitrogen website and they 
represent the sense and antisense sequences contained with the 58 base pair 
nucleotide sequence that is transcribed. The following sequences were used to 
construct the shRNA plasmids: 
POSTN sense 5' - GCTTGGGACAACTTGGATTCT - 3', antisense 5' -
AGAATCCAAGTTGTCCCAAGC- 3'; 
!TGB3 sense 5' - GCTCA TTGTTGA TGCTT A TGG - 3', antisense 5' -
CCA T AAGCA TCAACAA TGAGC - 3'. 
These oligonucleotides were annealed and ligated into Agei/EcoRI digested 
pLKO vectors. Transformation of the ligation reaction was carried out using 
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competent JM1 09 bacteria (Promega) and selected on LB/amp agar. Plasmid 
DNA was isolated from bacterial colonies using Miniprep kits (Qiagen) and the 
presence of the correct shRNA verified by DNA sequencing . Midiprep plasmid 
isolation kits (Ciontech) were used for larger scale plasmid isolation of confirmed 
pLKO plasmids containing the desired nucleotide sequences. Lentiviral particles 
were generated by co-transfection of the pLKO plasmid, psPAX2 and pMD2.G, in 
a 5:3:1 ratio , in 293FT cells, which were allowed to produce virus for 48 hours. 
Target cells were transduced with the harvested media in the presence of 
polybrene. Pooled cells were selected by treatment with 2 j..lg/ml of puromycin for 
two weeks. Knockdown was confirmed at both the RNA and protein level. 
Periostin ELISA 
Secreted periostin was measured with an ELISA kit (AdipoGen) according 
to the manufacturer's protocol. Briefly, one million cells were grown in serum-
reduced media (0.1 %) and conditioned media was collected 24 hours later. The 
protein was concentrated with using Amicon centriguation filters (30K membrane, 
Millipore) prior to analysis. 
Proliferation assay 
Two thousand cells per well were seeded in 96-well plates. Cell numbers 
were determined at baseline and every 24 hours with the Ce11Titer96 Aqueous 
Non-Radioactive Proliferation Assay (Promega) by measuring the absorbance at 
490 nm with j..IQuant plate reader (Bio-Tek). 
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Limiting dilution analysis 
SUM159 shGFP and shPN cells expressing firefly luciferase were 
generated though stable transfection with a MSCV-PGK-Iuciferase-hygromycin 
vector (Addgene) . Prior to injection, the cells were trypsinized , counted and 
resuspended in serum-reduced media (0.1% serum). Five hundred or fifty 
thousand cells were injected subcutaneously into female 6-8 week old 
NOD/SCID mice (The Jackson Laboratory) . Tumor growth was monitored 
weekly for six months using bioluminescent imaging (IVIS, Caliper) . 
Statistical analysis 
Statistical analysis was performed using a two-tailed paired Student's t-test. 
A P value less than 0.05 was considered statistically significant. Error bars 
represent SEM. 
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RESULTS 
Characterization of cancer stem cell phenotypes in M cells 
To identify genes that could regulate the cancer stem cell state , we began 
by studying a previously generated series of cell lines that mimics breast cancer 
progression243 ·244 . This model system is comprised of three cell lines: MCF1 OA 
(MI) and two derivatives of this line, MCF10AT1k.cl2 (Mil) and MCF10CA1h 
(Mill). Ml cells are a spontaneously immortalized cell line with no tumorigenic 
capacity and they are most representative of normal mammary epithelial cells . 
Mil cells were generated through ectopic expression of oncogenic H-RAS (G12V) 
in Ml cells244 and are tumorigenic, typically generating benign hyperplastic 
lesions when engrafted in immunocompromised mice. However, some Mil cells 
(approximately 25%) spontaneously progress to carcinomas and Mill cells were 
isolated from one of these malignant tumors; when re-injected these cells 
generate low grade, well-differentiated cancers243 . Previously work from our 
laboratory revealed that these lines exhibit distinct phenotypes in terms of their 
morphology and expression of epithelial marker genes245 . Ml and Mil cells 
exhibit a cobblestone , epithelial-like morphology and express high levels of 
epithelial-associated genes such as E-cadherin. On the other hand , Mill cells 
appear spindle-like, a characteristic mesenchymal phenotype, and have reduced 
E-cadherin expression , along with up-regulation of mesenchymal genes such as 
vimentin and N-cadherin. Consistent with this, Mill cells express significantly 
higher levels of EMT-inducing transcription factors such as FOXC2 and SIP1 . 
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Thus, Mill cells underwent an EMT during the progression to a carcinoma. The 
basic characteristics of the M cell line are summarized in Table 1. 
Table 1. Characteristics of the M cell lines 
Name Abbreviation Tumorigenicity Representative EMT 
Stage 
MCF10A Ml Non- Normal Epithelial 
tumorigenic mammary 
epithelium 
MCF10AT1k.cl2 Mil Mostly benign Premalignant Epithelial 
hyperplasia; epithelium 
occasionally 
carcinoma 
MCF10CA1h Mill Low grade, Carcinoma Mesenchymal 
well-
differentiated 
carcinoma 
Given the connection between EMT and cancer stem cells221 ·222 , we 
hypothesized that Mill cells might exhibit characteristics associated with stem-
like cancer cells. In support of this notion Mill cells were predominantly 
CD44+/CD24- (Figure 4) and preferentially formed mammospheres (Figure 5). 
Ml and Mil cells were mostly CD44+/CD24+ and were largely unable to generate 
mammospheres. Therefore, Mill cells phenotypically resemble breast cancer 
stem cells and we reasoned that they could serve as a good model to identify 
regulators of the cancer stem cell state. 
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Figure 4. CD44/CD24 analysis of the M cell lines. Flow cytometry was used 
to evaluate the surface expression of CD44 and CD24 in Ml, Mil and Mill cells . 
Representative flow cytometry plots are shown for each cell line. The histogram 
displays the percentage of CD44+/CD24- cells in each line, n=3. * P < 0.05, ** P 
< 0.01, error bars represent SEM. 
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Figure 5. Mammosphere formation potential of M cells. Mil and Mill cells 
were grown as mammospheres for 7-10 days prior to quantification and imaging. 
The histogram shows the number of mammospheres formed for every 1000 cells 
seeded, n=3. Ml cells could not reliably form mammospheres. ** P < 0.01, error 
bars represent SEM. 
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Periostin is highly expressed in cancer stem cell-enriched populations 
Since all of the M cells share the same genetic background, we 
hypothesized that alterations in gene expression were responsible for the 
maintenance of the Mill line in a cancer stem cell-like state. Thus, we sought to 
identify regulators of cancer stem cells by examining gene expression profiles of 
the different M cells. We had available to us the genes differentially expressed 
between Mil, Mill and Mill cells with inhibition of the TGF-13 signaling pathway, 
achieved through overexpression of the inhibitory SMAD, SMAD7245 . In Mill 
cells , overexpression of SMAD7 led to a partial reversal of EMT, along with 
altered epigenetic regulation of critical EMT genes such as E-cadherin245 . In 
searching for genes that could induce or maintain the cancer stem cell phenotype 
in Mill cells we focused on the genes that were overexpressed in Mill cells 
versus Mil cells, which were then repressed in MIII-SMAD7 cells. As Mill cells 
display sustained TGF-13 signaling245 , and since TGF-13 can push cells through an 
EMT and thereby into a cancer stem cell state221 , this cluster of genes was likely 
to harbor effectors of this signaling pathway that may be relevant in the context of 
cancer stem cells . 
This cluster contained a large number of genes - 293 genes were 
significantly repressed following overexpression of SMAD7 - and therefore we 
first narrowed down this list by considering only the most highly repressed genes. 
The third most repressed gene, periostin (POSTN) stood out for a number of 
reasons . First, periostin has been linked to the EMT-state 105. Second it is a 
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direct target of the transcription factor Twise46 and it is induced downstream of 
the TGF-13 pathwai 04 , two factors that promote passage through EMT and 
acquisition of stem cell phenotypes221 . Third , there was a loose connection to 
mammary stem cells , as periostin is overexpressed in BRCA 1 mutant cells and 
BRCA 1 loss has been linked to the abnormal expansion of mammary stem and 
progenitor cells247 ·248 . Thus, we speculated that tumor cell-derived periostin was 
important for the maintenance of a cancer stem cell phenotype. 
Using qRT-PCR we confirmed that the levels of periostin mRNA are 
significantly increased in Mill cells compared to Ml or Mil cells (Figure SA). As 
expected, the increased transcription of periostin in Mill cells is correlated with 
enhanced secretion of the protein into the surrounding media (Figure 68) . 
A. B. 
POSTN 
1.2 
Ml Mil Mill 
c: 
0 
·;;; 0.8 Ill Periostin Q) 
... 
c. 
)( 0.6 . w 
Q) 
> :;::; 0.4 * Ill Ponceau 
a; 
n:: 
O.: ___ ~_o_ 
Ml Mil Mill 
Figure 6. Periostin is highly expressed in Mill cells. A. Expression of POSTN 
in the M cell line was measured using qRT-PCR. B. Western blot analysis for 
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POSTN in media conditioned from the M cell lines. Ponceau staining of the 
membrane is used to show protein loading. * P < 0.05, ** P < 0.01, error bars 
represent SEM. 
Moreover, we validated that periostin is a transcriptional target of TGF-13 
signaling in this model of breast cancer. Treatment of Mil cells with TGF-13 
resulted in a dramatic increase in the transcription of periostin (Figure 7 A). 
Conversely, active TGF-13 signaling was necessary to sustain the expression of 
periostin in Mill cells because inhibition of this pathway, by either overexpression 
of SMAD? or knockdown of SMAD2, led to a significant reduction in periostin 
expression (Figure 78). 
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Figure 7. Periostin is a transcriptional target of TGF-J3 signaling in M cells. 
A. Mil cells were treated with TGF-131 (1 0 ng/ml) , or vehicle control, for 24 hours 
prior to RNA isolation. Periostin expression was measured by qRT-PCR. B. 
Periostin expression was assessed in Mill cells with stable expression of 
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SMAD7, or an shRNA directed at SMAD2, and control cells (pB and shGFP, 
respectively). Western blot shows SMAD7 overexpression or SMAD2 
knockdown in the respective cell lines. * P < 0.05, ** P < 0.01, error bars 
represent SEM. 
To see if periostin expression is associated with the cancer stem cell 
state, we experimentally enriched for cancer stem cells using two different 
approaches. In one, Mill cells were grown in both standard adherent culture and 
as mammospheres, which are predominately formed by cancer stem cells218 , and 
compared the expression of periostin under these conditions. Periostin 
expression was nearly 1 0-fold higher in Mill mammospheres than in Mill cells 
grown in two-dimension culture (Figure 8A). In a second approach , the 
expression of periostin was evaluated in two different fractions of Mil cells: the 
CD44+/CD24+ population (non-cancer stem cells) and the CD44+/CD24-
population (cancer stem cells), which represents approximately 25% of the total 
Mil population. Even in Mil cells, periostin levels were significantly increased in 
the CD44+/CD24- population of cells (Figure 88). Thus, in this breast cancer 
model, high periostin expression is correlated with multiple phenotypes attributed 
to cancer stem cells: residence in the EMT state, mammospheres formation and 
display of the CD44+/CD24- surface phenotype. 
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Figure 8. Periostin is highly expressed in cancer stem cell-enriched 
populations. A. Periostin expression was assessed by qRT-PCR in Mill cells 
grown under standard adherent culture and in mammospheres generated by Mill 
cells. B. Mil cells were fractionated based on the expression of CD44 and CD24 
(into CD44+/CD24- and CD44+/CD24+ populations) prior to RNA isolation and 
measurement of periostin expression by qRT-PCR. The flow cytometry plot 
below shows the different cellular populations that were isolated. * P < 0.05, ** P 
< 0.01, error bars represent SEM . 
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A periostin-integrin signaling axis in basal-like breast cancer cells 
In examining the gene expression profiles of the M cell lines, we noted 
that, in addition to periostin, Mill cells expressed high mRNA levels of integrin 133 
(ITGB3), a subunit of the integrin avl33 complex that is a known receptor for 
periostin 100 . Therefore, we hypothesized that periostin could signal in an 
autocrine/paracrine fashion via engagement of this integrin receptor. Consistent 
with this notion, the surface levels of integrin avl33 are abundant on Mill cells but 
almost completely absent from Ml and Mil cells (Figure 9). The presence of this 
intact signaling axis suggested that periostin could potentially signal through this 
integrin complex in Mill cells. 
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Figure 9. Expression of integrin avf33 on the surface of M cells. Ml , Mil and 
Mill cells were stained with LM609, an antibody that recognizes the integrin av~3 
complex, and analyzed by flow cytometry. Gray shading indicates isotype 
control. 
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To examine whether such an axis was present in other breast cancer 
cells, or whether it was restricted to only Mill cells, we measured the expression 
of both periostin and integrin J33 in a panel of nine breast cancer cell lines (MDA-
MB-468, SUM149, T47D, UACC812, MDA-MB-453, BT549, SUM1315, SUM159 
and Hs578T). High expression of both periostin and integrin J33 was detected in 
four cells lines- BT549, SUM1315, SUM159 and Hs578T cells (Figure 1 0). It is 
notable that, similar to Mill cells245 , all four of these cell lines are classified as 
basal-like breast cancer cells249 . 
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Figure 10. Periostin and integrin (33 are co-expressed in a subset of basal-
like breast cancer cell lines. The expression of periostin and integrin J33 was 
measured in a panel of nine breast cancer cell lines using qRT-PCR. The 
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expression values are presented relative to MDA-MB-468 cells , which expressed 
the lowest level of periostin. Black and red diamonds indicate classification as 
basal-like and luminal breast cancer cell lines, respectively. The black circle 
highlights the four cell lines that co-express high levels of periostin and integrin 
j33. 
We next assessed whether the elevated transcript levels of periostin and 
integrin 133 correlated with increased protein expression . In a subset of these 
lines, conditioned media was collected , concentrated , and subjected to western 
blot analysis to determine the amount of secreted periostin . In line with the qRT-
PCR data, SUM159 and Hs578T cells produced abundant periostin while none 
could be detected in T47D , UACC812 and SUM149 cells (Figure 11A). 
Moreover, SUM159, Hs578T, SUM1315 and BT549 cells displayed the highest 
surface levels of the integrin avl33 complex (Figure 11 B). These data indicate 
periostin-integrin signaling axis is present and potentially operative in a subset of 
basal-like breast cancer cells. 
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Figure 11. A subset of basal-like breast cancer cells produces periostin and 
exhibits high surface levels of integrin avJh A. Western blot analysis for 
periostin in the media conditioned from the indicated cell lines. Ponceau staining 
of the membrane is used to show protein loading. B. Flow cytometry of cells 
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stained with LM609 was used to measure the surface levels of the integrin Ov~3 
complex in the indicated cell lines. 
Generation of breast cancer cells with knockdown of periostin 
To test the relevance of periostin expression to the cancer stem cell state 
we selected two cell lines, Mill and the SUM159 line, which has a well-defined 
cancer stem cell population220 , and, through stable expression of an shRNA 
construct, established cell lines with knockdown of periostin (shPN) . By analysis 
of mRNA expression , periostin levels were reduced to roughly 25% of the 
transcript levels found in control cells (shGFP) (Figure 12A and Figure 12C). 
On the protein level , periostin expression was decreased in cell lysates prepared 
from shPN cells and while secreted periostin protein , as assessed by ELISA, was 
readily detectable in the media from control Mill or SUM159 cells , it was reduced 
nearly 15-fold in the periostin knockdown cells (Figure 128 and Figure 120). 
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Figure 12. Establishment of periostin knockdown cells. A. Periostin 
expression was measured by qRT-PCR in control (shGFP) and periostin 
knockdown (shPN) Mill cells. B. An ELISA assay was used to measure periostin 
secretion in the indicated Mill cells. Inset shows western blot analysis for 
periostin expression in cell lysates from the same cell lines. C. Periostin 
expression was measured by qRT-PCR in the indicated SUM159 cell lines. D. 
An ELISA assay was used to measure periostin secretion in the indicated 
SUM159 cell lines. Note that because periostin was not detected in shPN cells, 
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the histogram depicts the limit of detection for this assay, 8 ng/ml. Inset shows 
western blot analysis for periostin expression in cell lysates from the same cell 
lines. * P < 0.05, ** P < 0.01 , error bars represent SEM. 
Knockdown of periostin in Mill or SUM159 cells did not have an effect on 
cell proliferation or the morphological characteristics of either cell line, which 
retained their mesenchymal phenotype (Figure 13A-D). 
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Figure 13. Proliferation and morphology of periostin knockdown cells. A. 
The proliferation of the indicated Mill cells was assessed using an MTS assay. 
B. Photomicrograph to show the morphology of the indicated Mill cells. C. The 
proliferation of the indicated SUM159 cells was assessed using an MTS assay. 
D. Photomicrograph to show the morphology of the indicated SUM159 cells. 
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The effect of periostin knockdown on cancer stem cell phenotypes 
Next we sought to examine various cancer stem cell phenotypes in the 
periostin knockdown cell. In both Mill and SUM159 cells periostin knockdown 
resulted in a significant reduction in the number of mammospheres formed ; Mill 
shPN cells formed 52% fewer mammospheres while SUM159 shPN formed 29% 
fewer mammospheres, relative to their respective control cells (Figure 14A-8). 
However, knockdown of periostin had no effect on the CD44/CD24 surface 
phenotype in either M II I or SUM 159 cells and both retained a predominately 
CD44+/CD24- profile (Figure 15A-B). 
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Figure 14. Periostin knockdown impairs mammosphere formation. A. Mill 
shGFP or shPN cells were grown as mammospheres and quantified . B. 
SUM159 shGFP or shPN cells were grown as mammospheres and quantified. 
The data represent three independent experiments, each with an n=3. * P < 
0.05, ** P < 0.01 , error bars represent SEM . 
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Figure 15. Periostin knockdown does not alter the CD44/CD24 surface 
phenotype. A. Control (shGFP) and knockdown (shPN) Mill cells were stained 
for CD44 and CD24 prior to analysis by flow cytometry. B. Control (shGFP) and 
knockdown (shPN) SUM159 cells were stained for CD44 and CD24 prior to 
analysis by flow cytometry. 
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However, the most dramatic effect of periostin knockdown was observed 
in the well-established220 ALDH-positive , cancer stem cell population of SUM159 
cells. Under conditions of reduced serum (0.1% serum) , which are often used to 
analyze the effect of ECM proteins and integrin signaling250 , the ALDH-positive 
population accounted for close to 15% of the cancer cells. In SUM159 shPN 
cells , the ALDH-positive population was , remarkably, reduced to only 2% of all 
cells , representing a 7.4 fold reduction in this highly tumorigenic cell population 
(Figure16A-B). No changes in the ALDH population were noted in Mill cells . 
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Figure 16. Periostin is required for the maintenance of the ALDH-positive 
population in SUM159 cells. A. Representative ALDH plots of SUM159 control 
or periostin knockdown cells . After 48 hours of growth in serum-reduced media , 
the cells were stained using the ALDEFLUOR assay for 30 minutes prior to 
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analysis by flow cytometry. DEAB, an inhibitor of ALDH, is used as a gating 
control. B. Quantification of the percentage of ALDH-positive cells in SUM159 
shGFP and shPN cells in three independent experiments. * P < 0.05, error bars 
represent SEM. 
Since the ALDH-positive subpopulation of SUM159 cells has been 
demonstrated to be highly tumorigenic220 ·251 we wished to test whether 
knockdown of periostin impaired the ability of SUM159 cells to seed tumors . 
With a limited cohort of animals we found that while both SUM159 shGFP and 
shPN cells were able to initiate tumors when 500,000 cells were injected , when 
the number of injected tumor cells was reduced 1 0-fold only shGFP cells (50% 
success, versus 0% for shPN cells) were capable of seeding tumors (Table 2). 
Collectively, these results imply that periostin expression is intimately associated 
with the cancer stem cell state and is required to sustain numerous phenotypes 
associated with cancer stem cells including, mammosphere formation , an ALDH-
positive subpopulation and tumorigenicity. 
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Table 2. Limiting dilution analysis of SUM159 shGFP and shPN cells 
500,000 cells 50,000 cells 
SUM159 shGFP 1/1 (100%) 2/4 (50%) 
SUM159 shPN 1/1 (100%) 0/4 (0%) 
Note: the table indicates the tumor mc1dence rate. 
lntegrin (33 and cancer stem cell phenotypes 
If periostin is in fact acting through the integrin avJ33 complex to regulate 
the cancer stem cells , we reasoned that this receptor should also be important in 
the maintenance of cancer stem cell phenotypes. Two complementary pieces of 
evidence support this idea. 
First, Mill cells that are sorted by flow cytometry into two separate 
populations based on the surface levels of the integrin avJ33 complex have a 
dramatically different potential to initiate mammosphere growth . Mill cells with 
high levels of integrin avJ33 robustly form mammospheres, doing so at rate 4.9 
times that of cells negative for integrin avJ33 (Figure 17). 
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Figure 17. lntegrin avl33 expressing cells preferentially form 
mammospheres. Mill cells were sorted by flow cytometry based on the surface 
expression of the integrin avJ33 complex (antibody, LM609) prior to seeding an 
equal number of cells for mammosphere growth, n=3. * P < 0.05, error bars 
represent SEM. 
Second, we established SUM159 cells with knockdown of integrin J33 
(shBeta3) (Figure 18A). When these cells were grown as mammospheres, 
knockdown of integrin J33 led to a 50% reduction in the number of 
mammospheres formed (Figure 188). Moreover, SUM159 shBeta3 cells had a 
2.9 told reduction in the ALDH-positive cancer stem cell population (Figure 19). 
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Thus, integrin 133, likely in complex with integrin av, is also necessary for 
the maintenance of cancer stem cell-related traits such as mammosphere growth 
and ALDH activity. The overlapping phenotypes observed in cells with 
knockdown of periostin and cells with knockdown of integrin 133 suggest that 
periostin may signal through this integrin to regulate cancer stem cells. 
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Figure 18. Knockdown of integrin 133 impairs mammosphere formation. A. 
Flow cytometric analysis of the surface levels of integrin 133 (CD61) on control 
(shGFP) and knockdown (shBeta3) SUM159 cells. B. SUM159 shGFP or 
shBeta3 cells were grown as mammospheres and quantified . The data 
represent three independent experiments, each with an n=3. The shGFP data is 
reproduced here from Figure 148 for comparison. * P < 0.05, error bars 
represent SEM. 
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Figure 19. lntegrin 133 is required for the maintenance of the ALDH-positive 
population in SUM159 cells. A. Representative ALDH plots of SUM159 control 
or integrin J33 knockdown cells. After 48 hours of growth in serum-reduced 
media , the cells were stained using the ALDEFLUOR assay for 30 minutes prior 
to analysis by flow cytometry. DEAB, an inhibitor of ALDH , is used as a gating 
control. B. Quantification of the percentage of ALDH-positive cells in SUM159 
shGFP and shBeta cells in three independent experiments. The shGFP data is 
reproduced here from Figure 168 for comparison . * P < 0.05, error bars 
represent SEM. 
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Periostin is associated with a poor prognosis in ER-negative breast cancer 
If periostin is indeed able to maintain cancer stem cells through activation 
integrin av~3 we reasoned that breast cancers in which this signaling axis is 
operative might be enriched with cancer stem cells and therefore associated with 
a worse prognosis. One would predict that this would be limited to a subset of 
periostin-expressing basal-like breast cancer cells, which are typically ER-
negative but positive for integrin ~3252 . In accordance with this hypothesis, in 
silica analysis of a publically available breast cancer dataset253 revealed that high 
periostin expression was associated with reduced relapse-free survival in ER-
negative (HR=1.52, P= 0.0077), but not ER-positive (HR=1.04, P=0.66) breast 
cancers (Figure 20A and 208). 
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Figure 20. Periostin expression is associated with a poor prognosis in ER-
negative breast cancer. A. In silica Kaplan-Meier analysis of relapse-free 
survival in ER-negative breast cancer. Patients were divided into two groups 
based on the median expression level of periostin, n=457. B. Same as in A. but 
in ER-positive breast cancer, n=1 ,413. 
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DISCUSSION 
The cancer stem hypothesis has been put forth to explain the cellular 
heterogeneity that exists within a given cancer and posits that tumors are 
organized hierarchica11l7·53 . Therefore, in cancers that follow this model, 
tumorigenesis, and likely disease progression, is being driven and sustained 
primarily by a population of cancer stem cells254 . While still somewhat 
controversial255 , the biologic and clinical implications of cancer stem cells are 
vast and so this field has received an abundance of attention in recent years ; a 
PubMed literature search of the term "cancer stem cells" returns nearly 1 00 times 
more articles in the past ten years than in the ten years that followed the 
pioneering studies of leukemic stem cells in 199444 . From this large collection of 
work a few salient features of cancer stem cells have emerged. 
Highly tumorigenic breast cancer stem cells were first described in 2003 
when they were identified using the CD44high/CD2410w cell surface phenotype207 . 
In normal mammary epithelial cells and breast cancer, there is a strong 
connection between the mesenchymal cell state that results from induction of 
EMT and the acquisition of numerous phenotypes associated with stem-like 
cells221·256 . Working with a MCF1 OA-based cell line model of breast cancer 
progression our initial observations are consistent with this idea. The carcinoma 
line- Mill cells- appear mesenchymal morpholog ically , highly express multiple 
EMT-inducing transcription factors and, at the protein level, show suppression of 
E-cadherin along with overexpression of N-cadherin and vimentin245. Flow 
68 
cytometric analysis clearly demonstrated that Mill cells predominately displayed 
the CD44+/CD24-surface phenotype while Ml and Mil cells , which are epithelial 
in nature, were mostly CD44+/CD24+. This is substantiated by the fact that Mill , 
but not Ml or Mil , cells efficiently generated non-adherent mammospheres, a 
characteristic of normal and cancerous stem-like cells216·219 . Finally, Mill cells 
exhibit hyperactivation of the TGF-13 signaling pathwal45 , which is a potent 
inducer of EMT and has been demonstrated to enrich for cancer stem cells221 ·222 . 
Collectively, these data indicate that the Mill line is enriched with cells that share 
many traits associated with the cancer stem cell state and they suggest that this 
state may be maintained through autocrine/paracrine activation of the TGF-13 
pathway. The generation of EMT-induced cells has been successfully used to 
screen for selective inhibitors of cancer stem cells231 and we reasoned that Mill 
cells could represent a similar cell line model in which to study regulators of the 
cancer stem cell state. 
In examining gene expression profiles of the various M cells we were 
struck by one gene in particular- periostin (POSTN) . For one, periostin was the 
third most highly expressed gene in Mill cells , compared to Mil cells , that was 
also down-regulated upon inhibition of the TGF-13 pathway via overexpression of 
SMAD7. Periostin has been reported to be a direct transcriptional target of TGF-
13 signaling 104 and we have strong evidence to suggest this is likely the case in 
the M cell line, as TGF-13 treatment was sufficient to induce periostin expression 
in Mil cells and was necessary to sustain periostin expression in Mill cells. 
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Therefore, it seemed plausible that if active TGF-~ signaling is required for Mill 
cells to remain in a mesenchymal state245 - a state tightly linked to the cancer 
stem cell characteristics also exhibited by Mil cells - and if TGF-~ is a 
transcriptional regulator of periostin expression , then , perhaps, periostin could be 
an important regulator of the cancer stem cell state. Additionally, periostin was 
reported to be transcriptionally activated in the first study to examine the gene 
expression pattern of mammospheres216 . Our data, obtained using the M cell 
line, provide additional support to the idea that periostin expression is associated 
with cancer stem cell traits, being highly expressed in both mammospheres 
formed by Mill cells and in the CD44+/CD24- subpopulation of Mil cells. At the 
time, multiple studies reported that periostin was overexpressed in various types 
of cancer and in breast cancer it had been associated with metastasis and 
angiogenesis 100 , but a link to cancer stem cells was unknown. 
Interestingly, an integrin important for periostin signaling 168 , integrin ~3 
(ITGB3) , was also overexpressed in Mill cells and we were able to confirm that 
this was associated with remarkably higher surface levels of the functional 
integrin av~3 complex. Thus, Mill cells secreted a ligand, in this case an ECM 
protein , for which they also possessed a receptor- a classic paradigm in cancer 
biology. We found an intact periostin-integrin ~3 signaling axis - where the 
tumor cells secrete periostin and have abundant surface levels of integrin av~3 -
in a number of other breast cancer cell lines and in each case the cells were 
classified molecularly as basal-like breast cancer. This is notable for a couple of 
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reasons. First, numerous lines of evidence support the idea that basal-like 
breast cancer arises from transformation of luminal progenitor cells28·248 ·257·258 , 
which are specifically marked by expression of integrin ~3259 . It seems likely 
then, that many basal-like breast cancers express integrin ~3 (in our limited panel 
of cell lines, we detected this in 66.7% of basal-like lines) and, therefore, the 
presence of a functional signaling axis is likely to depend on the production of 
periostin. One study has found that periostin expression is associated with triple-
negative breast cancer, the majority of which fall under the basal-like 
classification 193. Second, basal-like cancer cells share numerous phenotypic 
similarities with breast cancer stem cells including a similar CD44+/CD24- surface 
marker profile260 , activation of a mesenchymal transcriptional program261 , and 
resistance to chemotherapl27 . This may be especially true of a related disease 
subtype, claudin-low breast cancers, that have an expanded cancer stem cell 
population262 ·263 . 
We tested the relevance of periostin expression to breast cancer stem 
cells by establishing two cell lines, Mill and SUM159, with stable knockdown of 
periostin . We found that this resulted in impaired mammosphere formation in 
both cell lines. The effect on mammosphere formation, while statistically 
significant, was somewhat modest. This may be due to the expression of other 
integrin receptors, ECM proteins or cell adhesion molecules, which could 
regulate similar pathways as periostin that might be important for mammosphere 
growth or survival. The depletion of ALDH-positive in SUM159 shPN cells is an 
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especially important finding because in numerous studies this cellular 
compartment has been validated to contain functional cancer stem cells , capable 
of initiating tumor grown at limiting dilution220·251 ·264 . Indeed, our pilot limiting 
dilution analysis , notwithstanding the limited animal numbers, supports the idea 
that SUM159 shPN cells may have an impaired ability to initiate tumor growth. 
However, we did not observe any changes in the percentage of cells displaying 
the CD44+/CD24- surface marker. This is consistent with a previous report which 
described the role of tenascin-C, another ECM protein that physically interacts 
with periostin 109 , in the regu lation of stem cell phenotypes during metastatic 
growth241 . In this study, tenascin-C was required for mammosphere growth 
without changing the CD44/CD24 surface phenotype241 . Therefore , functional 
heterogeneity exists within the CD44+/CD24- cancer cell population , with only a 
subset of these cells harboring high ALDH activity and having the ability to 
generate mammospheres. It is not known at present whether these two ECM 
proteins depend on each other to regulate cancer stem cell phenotypes or 
whether they represent redundant oncogenic pathways. 
Our data also demonstrate a role for the integrin av~3 receptor in 
mammosphere growth and maintenance of an ALDH-positive subpopulation. 
Mill cells sorted for high surface levels of this complex clearly generate more 
mammospheres. There are two potential explanations for this. For one, this 
could indicate that nearly all- approximately 80%- of the Mill cells that have an 
inherent ability to generate mammospheres are contained with in the integrin av~3 
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expressing subpopulation and thus, this effectively labels cancer stem-like cells. 
Alternatively, expression of this integrin receptor could provide cancer stem cells 
with a survival, proliferative or self-renewal advantage. Given that knockdown of 
integrin J33 in SUM159 cells resulted in significant reductions in the number of 
mammospheres as well as depletion of ALDH-positive cells, this argues for a 
functional role of this integrin. Another study has addressed the relationship 
between integrin J33 and cancer stem cells and reported that, while integrin J33 is 
highly expressed in breast cancer stem cells, knockdown of this gene resulted in 
minimal effects on mammosphere growth265 . However, these experiments were 
performed in derivatives of SK-BR-3 cells, a luminal cell line, and as argued 
above this specific integrin may be more relevant in the context of basal-like 
breast cancer. Nevertheless, the fact that both periostin and integrin J33 
knockdown resulted in similar phenotypes strongly suggests that these proteins 
function in the same pathway to regulate breast cancer stem cells. 
In addition to the experiments presented in this chapter, others have 
recently found that periostin is required for the maintenance of breast cancer 
stem cells 118 . This was accomplished through an entirely different approach, 
using a genetic model of breast cancer metastasis. But, similar to our studies , 
periostin expression was regulated by TGF-J3 signaling and required for efficient 
formation of mammospheres; furthermore, it was essential for metastatic 
outgrowth of the cancer stem cell population 118 . Interestingly, periostin was 
expressed in physiologic niches associated with stem cells in the breast, skin and 
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intestine 11 8 . Other studies have also found that human mammary stem cells 
express relatively high level of periostin248 . This raises the possibility that 
periostin typically regulates adult stem cells but is co-opted in the case of cancer, 
where it controls similar downstream pathways to sustain cancer stem cells. 
Our work, while consistent with the central idea that periostin is required 
for the maintenance of breast cancer stem cells , also differs in important ways, 
concerning both the source of periostin as well as how and where it can act. 
First, in their model periostin was derived from stromal fibroblasts 11 8 . Our work 
shows that a subset of breast cancer cells can produce periostin as well , 
potentially generating their own functional niche and rendering them more 
independent from their cellular microenvironment. Second , the relevance of 
integrin signaling was not articulated in their model and if the murine tumor cells 
express a different set of integrin receptors the mechanism of periostin action 
could be quite distinct. In fact, periostin was found to bind Wnt ligands, thereby 
enhancing signaling through this pathway. Finally, their study was limited to 
tumor cell colonization of the lung , where the resident fibroblasts secreted 
periostin in response to nascent metastatic colonies11 8 . If periostin can be tumor-
cell derived as well then it could , in principle , act in the primary tumor as well. 
We hypothesized that periostin signaling in the primary tumor might enrich 
for cancer stem cells and , therefore , periostin expression would be associated 
with a worse prognosis. Further, we predicted that this would be dependent on 
the presence of integrin 133. To address this question , we used in silica Kaplan-
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Meier analysis of a publically available breast cancer datasee53 and divided our 
analysis based on the expression of the ER. Although ER-negativity is not a 
perfect surrogate for basal-like breast cancers, which are likely to express 
integrin 133, there is a significant overlap between these two classifications25 and , 
thus, we could leverage a larger dataset. lntegrin 133 itself could not be reliably 
evaluated as prognostic marker because the average expression of the probe set 
was not high enough . But, in support of our model we found that high periostin 
expression in primary tumor samples was associated with reduced-relapse free 
survival in ER-negative cancers while no significant association was found in ER-
positive cancer. This is in accordance with a recent study that found a 
correlation between periostin expression , breast cancer stem cell content (as 
assessed by the percentage of CD44+/CD24- cells) and a worse clinical 
prognosis266 . As periostin has been suggested to promote angiogenesis through 
activation of integrin avl33 in endothelial cells 197 , it is possible that high periostin 
expression could be related to neoangiogenesis, which is also a prognostic factor 
in breast cance~67 . However, this would seem to be independent of ER status, 
suggesting an alternate explanation is conceivable. 
In conclusion , our studies indicate that, in a subset of basal-like cancer 
cells , a periostin-integrin 133 signaling axis is potentially operative. We have 
demonstrated that this signaling axis is necessary for the maintenance of 
numerous cancer stem cell trains, mainly the ability to sustain mammosphere 
growth and a subpopulation of ALDH-positive cells . Further, our findings suggest 
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that basal-like breast cancers can establish a supportive ECM niche, which may 
sustain a population of breast cancer stem cells. 
76 
CHAPTER 2: THE PATHWAYS REGULATED BY PERIOSTIN IN BREAST 
CANCER STEM CELLS 
BACKGROUND 
lntegrins and breast cancer 
Cells sense and respond to the ECM by way of transmembrane integrin 
receptors, which recognize and bind to various ECM proteins and thereby 
facilitate cell adhesion and intracellular signaling. lntegrins function as a 
heterodimer, consisting of one a subunit and one 13 subunit that associate non-
covalently. Mammals have 24 distinct integrin receptors, formed from a total of 
18 a subunits and 8 13 subunits73 , and these functional complexes couple 
recognition of ECM ligands to the assembly of the actin cytoskeleton and the 
activation of various intracellular kinases268 . lntegrin recognition of ECM proteins 
induces allosteric changes that allow the receptor to transduce this signal across 
the membrane, a process referred to as outside-in signaling; as integrins 
possess no enzymatic function, activation of integrin receptors results in the 
association of multiple protein complexes with the short cytoplasmic tails of the 
integrins73 . In this way, integrins can transmit mechanical signals to the actin 
cytoskeleton (and in the case of integrin 134, to intermediate filaments) through 
proteins such as a-actinin and paxillin as well as biochemical signals by way of 
tyrosine kinases such as FAK or SRC269 . lntegrin signaling occurs in cooperation 
and coordination with growth factor signaling that is initiated from soluble factors 
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in the extracellular environment. This makes sense as normal epithelial cells are 
anchorage-dependent and require adhesion, mediated by integrins, in order to 
proliferate in response to growth factors270 . Moreover, integrins and growth 
factor receptors can activate similar downstream signaling pathways including 
tyrosine kinases and the MAPK pathway, and this combined activation can 
further amplify these signaling cascades271 . lntegrin receptors are unique in that 
they can also transmit signals emanating from within the cell to the extracellular 
environment in what is known as inside-out signaling73 . In epithelial cells , this 
bidirectional communication allows integrins to control remodeling and 
reorganization of the ECM, which can potentially liberate occult soluble growth 
signals74 . 
lntegrins are not considered to be bona fide oncogenes or tumor 
suppressors but their expression levels are affected by transformation and breast 
cancer cells often show deregulation of integrin expression272 . No characteristic 
integrin expression pattern can be ascribed to all breast tumors and it is likely 
that different molecular subtypes of breast cancer have distinct patterns of 
integrin expression21 . Nevertheless, certain integrins are commonly deregulated 
in breast cancer. For example, integrins a6273 , ~4274 and av275 are generally 
overexpressed in aggressive breast cancer cells while the expression of integrin 
a2~/76 can be suppressed during the process of transformation. Numerous 
studies have established that integrins play a direct functional role in breast 
cancer cells , influencing transformation, survival , dissemination and 
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metastasis277•278 . Additionally, integrin signaling in tumor-associated stromal 
cells can also impact the development and progression of cance~79 . The integrin 
stimulated signaling pathways that are activated downstream of periostin in 
cancer cells are summarized in Figure 21 . 
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Figure 21. Periostin signaling pathways in cancer. This schematic 
summarizes the integrin receptors and downstream signaling pathways that can 
be activated , in various contexts, by periostin in caner cancer cells. For a more 
detailed explanation see the General Background and Literature Review. 
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lntegrins in normal and malignant stem cell biology 
In recent years, as the biology of both mammary stem cells and cancer 
stem cells has come into focus, integrins have emerged as markers and 
regulators of these distinct cell types . The identification of epithelial populations 
enriched with mammary stem cells, from which a single cell can reconstitute a 
functional gland , relied on purification schemes involving two integrins, integrin 
131 (CD29) and integrin a6 (CD49f) , and in both cases mammary stem cells 
expressed high levels of the respective integrins280·281 . Analogous studies have 
since been performed using human cells and a humanized mammary fat pad 
transplantation assay and, here too, high expression of integrin a6 (along with 
the absence of EpCAM expression) was used to purify a mammary stem cell 
enriched population248. The scope of these studies was not to address the role 
of integrins in mammary stem cells but the results almost certainly indicate that 
mammary stem cells possess a characteristic set of integrins and suggest that 
these integrins, and therefore distinct ceii-ECM interactions, might have a 
functional role in regulating the mammary epithelial cell hierarchy. 
This notion has received some support in recent years, mainly through the 
use of mammary-specific deletion of integrins. For example, targeted disruption 
of integrin 131 in ductal epithelial or luminal alveolar cells impaired lobuloalveolar 
development and lactation, which was attributed to inhibition of luminal cell 
proliferation as a result of increased p21 282 and failure to differentiate in response 
to prolactin283 . When integrin J31 was deleted from the basal cell population of 
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the mammary gland this resulted in a depletion of mammary stem cells and 
produced glands that lacked regenerative potential and dividing basal cells 
lacking integrin ~1 aberrantly gave rise to luminal cells284 . Interestingly, while 
integrin ~3 is not widely expressed in the mammary gland , it has been found to 
mark a subpopulation of luminal progenitors with the capacity to proliferate and 
differentiate into luminal epithelial cells259 . Cells with high surface expression of 
integrin ~3 form exclusively luminal colonies in vitro and , in vivo , this 
subpopulation of cells decreases with pregnancy, ostensibly as a result of 
increased luminal differentiation259 . Collectively, these studies support the idea 
that distinct ceii-ECM interactions are crucial for the regulation of a proper 
epithelial cell hierarchy in the mammary gland. 
Similar observations have been extended to the regulation of cancer stem 
cells as well. In the MMTV-Wnt1 model of breast cancer, it has been noted that, 
prior to tumor formation , there is an expansion of the CD29highCD24+ population 
of mammary stem cells285 . Furthermore, in this same model , integrin ~3 marked 
a population of cancer stem cells that was highly tumorigenic, implying that 
Wnt1-induced tumors may arise from an altered pool of luminal progenitors285. It 
remains to be seen , though , whether signaling downstream of integrin ~3 is 
relevant to the cancer stem cell state . However, FAK - a tyrosine kinase 
activated downstream of integrins82·286 - has been implicated in the control of 
cancer stem cells287 . When FAK was deleted in the MMTV-PyMT model of 
breast cancer, it led to impaired self-renewal and maintenance of a cancer stem 
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cell population, defined in part by the expression of integrin ~1 and ~3, that was 
associated with reduced tumorigenesis288 . Finally, it is notable that in prostate 
cancer integrin ~4 signaling has been linked to the self-renewal, and subsequent 
expansion of, a population of cancer stem cells289 . Thus, it is reasonable to 
speculate that integrin signaling, which plays important roles in the regulation of 
normal mammary stem cells, may be co-opted during the development of breast 
tumors and repurposed to function in highly malignant cancer stem cells. 
Signals that regulate breast cancer stem cells 
In addition to integrins, various other signaling pathways have been 
implicated in the regulation of breast cancer stem cells. Elucidating such 
regulatory networks has illuminated the underlying biology of these tumor cells 
and it is hoped that they will also serve as targets of future therapeutics designed 
to eliminate cancer stem cells 55 . Many of these signals, including the Wnt, Notch 
and Hedgehog pathway, constitute important developmental programs that, in 
breast cancer, may also act to sustain a population of cancer stem cells290 . 
The Wnt pathway probably provides the best evidence of this paradigm. 
In the mammary gland Wnt ligands, which act through transmembrane Frizzled 
proteins and the LRP5-LRP6 co-receptors291 , control epithelial cell fate decisions 
during embryogenesis and postnatal development as well as in response to 
pregnancy-induced changes in the gland292·293 . Indeed, mammary stem cells 
have been shown to directly respond to Wnt ligands and this promotes self-
renewal and expansion of this adult stem cell population294 . Consistent with this, 
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similar observations have been made in the hematopoietic system and hair 
follicle240 . Although mutations in the Wnt pathway are rare in breast cancer, the 
activation of this signaling pathway is often enhanced in tumors295 and transgenic 
expression of Wnt-1 leads to the development of hyperplastic lesions in the 
mammary gland296 , both of which imply that aberrant Wnt signaling is relevant in 
the context of breast cancer. Evidence for a role of the Wnt pathway in the 
regulation of cancer stem cells comes from studies that showed that Wnt-1 
driven murine breast cancers harbor a cancer stem cell population239, along with 
the observation that Wnt signaling is essential for the maintenance of cancer 
stem cells in a mouse model of skin cance~97 and marks a population of colon 
cancer stem cells298 . Furthermore, Dickkopf-1 (DKK) and secreted frizzled-
related protein 1 (SFRP1 ), both antagonists of Wnt signaling , can inhibit 
mammosphere formation and must be suppressed for breast cancer cells to 
remain in a mesenchymal , stem-like state224 . 
Similar to Wnt signaling , the Notch pathway has also been linked to both 
normal mammary development as well as breast cancer stem cells299·300. The 
Notch signaling pathway is unique in that in both the ligand (DELTA, JAGGED) 
and receptor (NOTCH) proteins are membrane-bound and , thus, acts to transmit 
signals between adjacent cells301 . Transgenic expression of constitutively-active 
Notch receptors is oncogenic in the mammary gland302 and human breast 
cancers have been demonstrated to show activation of this pathway as well303 . 
Using mammosphere culture it was shown that Notch could promote the self-
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renewal of mammary stem cells and clonogenic assays suggested that activation 
of the Notch signaling pathway also expanded the population of progenitor cells 
capable of myoepithelial differentiation304 . Activation of Notch signaling is 
required for breast cancer cells to efficiently generate mammospheres305 and, 
conversely, inhibition of the Notch pathway can impair mammosphere 
formation 306 , suggesting that cancer stem cells rely on this ancient 
developmental signaling mechanism. Further evidence for the role of Wnt and 
Notch signaling is provided by the finding that tenascin-C regulates metastasis-
initiating breast cancer cells , in part, by promoting the expression of leucine-rich 
repeat-contain G protein coupled receptor 5 (LGR5) and musashi homolog 1 
(MSI1) , mediators of the Wnt and Notch pathway, respectivel/41 . 
The Hedgehog pathways consists of various secreted ligands, such as 
sonic hedgehog (SHH) and desert hedgehog (DHH), which bind to Patched 
(PTCH 1) receptors in the plasma membrane to induce the activation of various 
GLI transcription factors307 . Interestingly, snail family zinc finger 1 (SNA/1), an 
EMT-inducing transcription factor, is a transcriptional target of GLI1 307 , indicating 
that a potential connection exists between Hedgehog signaling , EMT and stem 
cells290·307 . Hedgehog signaling , through the polycomb protein BMI1, has been 
shown to be important for the self-renewal of mammary stem and progenitor cells 
and CD44+/CD24- breast cancer stem cells highly express components of the 
Hedgehog pathwa/64 . Additional evidence for the relevance of this pathway to 
breast cancer is provided by a genetic mouse model that shows transgenic 
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expression of GLI1 can induce mammary tumors308 and by the finding that high 
levels of Hedgehog ligands are associated with the basal-like subtype of breast 
cancer and reduced survival309. 
Other factors that have been linked to the regulation of breast cancer stem 
cells include hormones and microRNAs. Progesterone can indirectly lead to an 
expansion of mammary stem cells during pregnancy that is likely in response 
receptor activator of nuclear factor-kappa-S ligand (RANKL)31 0·311 . Inhibition of 
RANK signaling in a medroxyprogesterone acetate (MPA) murine model of 
breast cancer resulted in delayed onset of tumorigenesis, a reduction in 
mammosphere formation and sensitization to radiotherapy, suggesting that the 
RANK pathway can also control the self-renewal of breast cancer stem cells312 . 
Given the connection between the RANKL-RANK signaling axis and 
metastasis313·31 4 , it is possible that this pathway could be important to 
disseminated cancer stem cells as well. Estrogen has also been found to control 
breast cancer stem cells; in ER-negative cancer this is reported to occur in a 
paracrine fashion , through the activation of fibroblast growth factor (FGF) 
signaling and downstream induction of the transcription factor T-box protein 3 
(TBX3)31 5 . Therefore, hormones that control the pool of adult mammary stem 
cells may also regulate breast cancer stem cells. Similar parallels exist on the 
level of microRNA regulation. For instance, let-7 and miR-200c are repressed in 
mammary stem and progenitor cells , and both have been demonstrated to limit 
the self-renewal capacity of breast cancer stem cells316-318 . Thus, although 
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cancer stem cells do not necessarily arise from transformation of mammary stem 
cells, they seem to share common regulatory pathways. 
Finally, cytokines have begun to emerge as critical regulators of the 
cancer stem cell state319·320 . Foremost here are the inflammatory cytokines 
interleukin-6 (IL-6) and interleukin-8 (IL-8), both of which can be regulated by the 
NF-KB pathwal20 . While a connection between inflammation and cancer has 
been recognized for some time321 , it is only relatively recently that their role in 
regulating breast cancer stem cells has been revealed. For instance, oncogenic 
activation of SRC can initiate an NF-KB-mediated inflammatory response in 
breast cancer cells that , through repression of let-7, leads to the up-regulation of 
IL-6 and subsequent activation of STAT3 signaling, which is required to maintain 
a population of cancer stem cells322 . This is in line with another study that found 
CD44+/CD24- stem-like cancer cells exhibit enhanced signaling through the IL-6-
JAK2-STAT3 signaling pathway, the activation of which was essential for the 
proliferation of these cells323 . IL-8 has been reported to be overexpressed in the 
ALDH-positive cancer stem cell population and treatment with recombinant IL-8 
can both enhance mammosphere formation potential and give rise to more 
ALDH-positive cancer cells220 . In further support of this idea, inhibition of 
chemokine C-X-C motif receptor 1 (CXCR1 ), a receptor for IL-8, compromised 
the viability of the cancer stem cell population, an effect that was attributed to 
impaired signaling through the FAK-AKT-forkhead box 03 (FOX03A) 
pathwal51 . These cytokines can be secreted by tumor cells or by bone marrow-
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derived mesenchymal stem cells324 and this cytokine network may underlie the 
equilibrium that exists between the cancer cells that reside in a stem-like state 
and those that do noe25 •326 . 
In this chapter we investigated the pathways downstream of periostin that 
we hypothesized would be relevant to the maintenance of breast cancer stem 
cells. 
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MATERIALS AND METHODS 
Cell culture 
SUM159 shGFP, shPN and shBeta3 cells were cultured in Ham's F/12 
supplemented with 5% FBS, 10 IJg/ml insulin and 0.5 IJg/ml hydrocortisone. Mill 
shGFP and Mill shPN cells were cultured in DMEM F/12 media containing 5% 
horse serum, 10 IJg/ml insulin , 20 ng/ml EGF, 0.1 ng/ml cholera toxin and 0.5 
IJg/ml hydrocortisone. Hs578T shGFP and shPN cells were maintained in DMEM 
containing 10% FBS. All cells were grown in media containing 1% 
penicillin/streptomycin and maintained at 3rC in a humidified incubator with 5% 
C02 . Each cell line was screened for mycoplasma with a PCR-based detection 
kit (Sigma-Aldrich). 
Secondary mammosphere formation assay 
To generate secondary mammospheres, following quantification as 
described in Chapter 1, the primary spheres were trypsinized , and the viability 
assessed with trypan blue exlusion. Two thousand viable cells were seeded in 
ultra-low attachment plates (Corning) in MammoCult media containing the 
proliferation supplement as well as 0.48 IJg/ml hydrocortisone and 1% 
methylcellulose and allowed to grow for 7-10 days. The number of secondary 
spheres was quantified as described above. 
Antibodies and reagents 
The following antibodies were used: periostin (BioVendor) , phospho-
STAT3 (tyrosine 705) , total STAT3, phospho-p65 (serine 536) , total p65, 
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phospho-ERK1/2 (threon ine 202/tyrosine 204) , total ERK (Cell Signaling 
Technology) and beta-actin (Sigma-Aldrich) . TNF-a (R&D Systems) was 
dissolved in DMSO and used at a final concentration of 10 ng/ml. PD184352 and 
U0126 (Sigma-Aldrich) , which are non-competitive MEK inhibitors, were 
dissolved in DMSO and used at a concentrations of 10 IJM and 25 1-JM , 
respectively. 
Genome-wide expression profiling 
Total RNA was isolated from three biological replicates for each cell line 
using Trizol (Life Technologies) , cleaned-up with the RNeasy Mini kit (Qiagen) , 
and the cRNA hybridized to human GeneChip 2.0 ST arrays (Affymetrix). The 
arrays were normalized using the robust multiarray average (RMA) algorithm, the 
probes mapped to human Entrez Gene IDs and the expression values log2-
transformed. To assess differential gene expression a linear model was created 
and one-way ANOVA performed. Genes with an FOR q < 0.01 (1182) were 
included in the analysis. Gene set enrichment analysis (GSEA) included gene 
sets from the Molecular Signatures Database (MSigDB). Ingenuity Pathway 
Analysis was used assess the upstream signaling networks associated with the 
gene expression signatures. 
Quantitative reverse transcription-PeR 
The following primers were used for qRT-PCR: 
!L6, forward 5' - AA TGAGGAGACTTGCCTGGT - 3' , reverse 5' -
GCAGGAACTGGATCAGGACT- 3'; 
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ILB, forward 5' - AAGACATACTCCAAACCTTTCCA - 3', reverse 5' -
CCAGACAGAGCTCTCTTCCA- 3'; 
WNT1 , forward 5' - CTTCGGCAAGATCGTCAAC - 3', reverse 5' -
GGATTCGATGGAACCTTCTG- 3'; 
WNT3A , forward 5' - TTTGCAGTGACACGCTCAT - 3', reverse 5' -
CAAACTCGATGTCCTCGCTA- 3'; 
AXIN2, forward 5' - GGAGAAA TGCGTGGATACCT - 3', reverse 5' -
CTGCTTGGAGACAATGCTGT- 3'; 
ACTB, forward 5' - CGAGCACAGAGCCTCGCCTTTGCC - 3', reverse 5' -
TGTCGACGACGAGCGCGGCGATAT- 3'. 
The following real time PCR program was used : 50°C, 2 min ; 95°C, 12 min ; cycle 
40x 95°C 20 sec, 5rC 1 min , 72oC 15 sec; 72oC 10 min. 
IL-8 ELISA 
Conditioned media was collected from one million cells grown for 24 hours 
in serum-reduced media (0 .1% serum) and the concentration of IL-8 determined 
using an IL-8 Quantikine ELISA kit according to the manufacturer's protocol 
(R&D Systems). 
Western blot anlaysis 
Cells on ice were lysed with RIPA buffer containing protease and 
phosphatase inhibitor cocktails (Roche). For examination of signaling events , 
cells were grown in serum-reduced media (0.1% serum) for 24 or 48 hours, as 
indicated , prior to protein isolation. Equal amounts of protein lysates were mixed 
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with Laemmli 's reducing buffer (Boston Bioproducts) , separated by SDS-PAGE 
and immobilized on PVDF membranes. Secondary antibodies were conjugated 
to peroxidase and detected by chemiluminescence with ECL solution (Perkin-
Elmer) . 
ALDEFLUOR Assay 
To quantify the percentage of ALDH-positive cells , the ALDEFLUOR 
assay was used (Stem Cell Technologies) . Briefly, cells were grown in serum-
reduced media (0.1% serum) for 48 hours, trypsinized , suspended in assay 
buffer and treated for 30 minutes with the ALDEFLUOR reagent (BODIPY-
aminoacetaldehyde, BAAA; 3 IJM) , in the presence or absence of the ALDH 
inhibitor diethylaminobenzaldehyde (DEAB; 37.5 !JM). Propidium iodide (PI)-
positive cells were excluded from the analysis. Samples were analyzed on a 
FACScan or FACSCalibur (SO) cytometer. Flow cytometry data was analyzed 
with FlowJo (Tree Star). 
Statistical analysis 
Statistical analysis was performed using a two-tailed paired Student's t-
test. A P value less than 0.05 was considered statistically significant. Error bars 
represent SEM . 
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RESULTS 
Genome-wide expression analysis of SUM159 cells with disruption of the 
periostin-integrin 133 signaling axis 
To understand the molecular events downstream of periostin signaling we 
examined gene expression profiles of SUM159 shGFP, shPN and shBeta3 cells. 
This cell line was chosen because of the dramatic reduction that was observed in 
the percentage of ALDH-positive cells and because the pilot limiting dilution 
analysis suggested a depletion of functional cancer stem cell in SUM159 shPN 
cells. In these experiments, and in experiments examining the activation of 
downstream signaling pathways described below, the cells were cultured under 
conditions of reduced serum (0.1% serum) in order to detect changes 
downstream of periostin . Such approaches are commonly used to investigate 
downstream ECM-integrin signaling pathways250 . Genome-wide expression 
analysis revealed that 1182 genes (AN OVA, FOR q < 0.01) were differentially 
expressed across the three cell lines (Figure 22A). Principal Component 
Analysis (PCA) showed that there was relatively little variability among the three 
biological replicates that were analyzed for each cell (Figure 228). Additionally , 
SUM159 shPN and shBeta3 clustered separately along the first principal 
component suggesting that, although these lines exhibit overlapping phenotypes 
in regards to cancer stem cell traits, they are still quite distinct. Therefore, to 
identify the pathways downstream of periostin we focused mainly on gene 
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expression changes between SUM159 shGFP and shPN cells that were also 
coordinately regulated in shBeta3 cells. 
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Figure 22. Genome-wide expression analysis of SUM159 shGFP, shPN and 
shBeta3 cells. A. Heat map depicting the 1182 genes differentially expressed 
between the three cell lines (AN OVA, FOR q < 0.01 ). Eight co-regulated clusters 
were identified by unsupervised hierarchical clustering analysis. Prior to 
microarray analysis , RNA was isolated from cells grown in serum-reduced media 
(0.1% serum) for 48 hours, n=3. Colors represent: blue, below mean expression; 
red , above mean expression . B. PCA plot shows the three cell lines cluster 
strongly by group. 
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Next we examined the most highly-repressed genes in SUM159 shPN 
cells relative to shGFP cells , which were also coordinately regulated in the 
shBeta3 line (Table 3). In concordance with the ALDEFLUOR analysis, 
aldehyde dehydrogenase 1, family member A 1 (ALDH1 A 1) was the top hit; 
another dehydrogenase, xanthine dehydrogenase (XDH) was also significantly 
repressed in both SUM159 shPN and shBeta3 cells. This list is populated by 
numerous other interesting genes including prostaglandin-endoperoxide 
synthase 2 (PTGS2) , interleukin 13 receptor, alpha 2 (IL 13RA2) , chemokine C-C 
motif receptor-like 1 (CCRL 1) , integrin ~4 (ITGB4), ILB and IL 1A. 
Table 3. Top genes repressed in SUM159 shPN that are coordinately 
regulated in sh8eta3 cells. 
Gene Fold FOR q 
Symbol Gene Name Change value 
aldehyde dehydrogenase 1 
ALDH1A1 family, member A 1 -16.08 0.0008 
prostaglandin-endoperoxide 
PTGS2 synthase 2 -8 .91 0.0011 
MPZL2 myelin protein zero-like 2 -6.43 0.0006 
interleukin 13 receptor, 
IL 13RA2 alpha 2 -4 .93 0.0006 
chemokine (C-C motif) 
CCRL1 receptor-like 1 -4.80 0.0007 
solute carrier family 35, 
SLC35F3 member F3 -4.78 0.0006 
ITGB4 integrin , beta 4 -4.31 0.0009 
XDH xanthine dehydrogenase -4.13 0.0009 
IL8 interleukin 8 -3.59 0.0010 
IL1A interleukin 1, alpha -3.56 0.0006 
95 
Repression of a cytokine network in SUM159 shPN and sh8eta3 cells 
To investigate the major pathways regulated by periostin we used Gene 
Set Enrichment Analysis (GSEA) to identify biological terms, pathways and 
processes that were perturbed in SUM159 shPN cells, relative to control (shGFP) 
cells. This analysis revealed six gene sets, containing a preponderance of 
cytokines, that were significantly repressed in SUM159 shPN cells which include 
those of the cytokine pathway, inflammatory pathway, hematopoietic cell lineage 
gene set, local acute inflammatory response (LAIR) pathway, synthesis of 
glycophosphatidylinositol (GPI) anchored proteins gene set, and the stem 
pathway (Table 4). 
Table 4. Top pathways repressed in SUM159 shPN cells. 
Source Gene Set Name NES FDRq 
BioCarta Cytokine pathway -2.19 0.0027 
Inflammatory 
BioCarta pathway -2.15 0.0041 
Hematopoietic cell 
KEGG lineage -2.08 0.0171 
BioCarta LAIR pathway -2.07 0.0159 
Synthesis of GPI 
Reactome anchored proteins -2.03 0.0294 
BioCarta Stem pathway -2.00 0.0368 
Note: NES denotes the normalized expression score for each gene set. 
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Given the connection between cytokines and breast cancer stem cell we 
wished to investigate this gene set further. Close examination of the twenty 
genes that comprise the cytokine pathway gene set revealed that five cytokines 
were clearly repressed in SUM159 shPN cells compared to shGFP cells: /L 1A, 
ILB, /L6, IL 18 and IL 16 (Figure 23). 
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Figure 23. Expression of the cytokine gene set in SUM159 shGFP and 
shPN cells. Heatmap depicts expression of the 20 genes contained in the 
BioCarta Cytokine Network gene set in SUM159 shGFP and shPN cells. Gene 
expression values are zero-centered by row and arranged in order by the 
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moderated t statistic. Colors represent: blue, below mean expression; red, above 
mean expression. 
Of these five cytokines, IL 1A, ILB, and IL6 were found at leading edge of 
other downregulated gene sets (Table 5), indicating that they may represent 
important mediators downstream of periostin. IL-6 and IL-8 were selected for 
further analysis, as they are known regulators of the cancer stem cell state319 . 
Quantitative RT-PCR was used to confirm the repression of /L6 and ILB 
expression in SUM159 shPN cells; furthermore, the expression of both genes 
was also significantly reduced in SUM159 shBeta3 cells (Figure 24) . 
Additionally , the amount of IL-8 secreted by SUM159 shPN and shBeta3 cells 
was significantly reduced compared to shGFP cells (Figure 25). Therefore 
SUM159 cells with knockdown of periostin or integrin ~3 exhibit impaired 
production of a distinct cytokine network in comparison to control cells. 
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Table 5. Leading edge analysis of gene sets repressed in SUM159 shPN 
cells. 
Note : Each row indicates a gene set and each column corresponds to a gene, 
with a shaded cell indicating that the gene was in the leading edge of the GSEA 
and an empty cell indicating that the gene was not present in the gene set. 
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Figure 24. Repression of IL6 and ILB expression in SUM159 shPN and 
sh8eta3 cells . IL6 and ILB mRNA levels were measured in the indicated 
SUM159 cell lines by qRT-PCR. RNA was isolated from cell grown in serum-
reduced media (0.1% serum) for 48 hours. ** P < 0.01 , error bars represent SEM . 
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Figure 25. Impaired IL-8 secretion in SUM159 shPN and shBeta3 cells. An 
ELISA assay was used to measure the levels of IL-8 in media conditioned from 
the indicated SUM159 cell lines. Media was conditioned for 48 hours in cells 
grown under serum-reduced conditions (0.1% serum). ** P < 0.01, error bars 
represent SEM. 
SUM159 shPN and sh8eta3 cells exhibit reduced STAT3 signaling 
In light of the reduced cytokine levels noted above, and because STAT3 is 
a transducer of cytokine signals that has been linked to the maintenance of 
breast cancer stem cells323 , we were prompted to investigate the STAT3 
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signaling pathway in cells with knockdown of periostin or integrin 133. Indeed, 
while SUM159 shGFP exhibited high levels of active, phosphorylated (tyrosine 
705) STAT3, both SUM159 shPN and shBeta3 cells had markedly reduced levels 
of phosphorylated STAT3 (Figure 26) . This weakened activation of STAT3 could 
be rescued by transient exposure of the knockdown cells to media conditioned 
from SUM159 shGFP cells, but not media conditioned from shPN cells (Figure 
27). These data suggest that impaired production of secreted factors from 
SUM159 shPN and shBeta3 cells - likely the cytokines mentioned above - are 
responsible for the observed reduction in STAT3 signaling, rather than any 
inherent intracellular defects. 
shGFP shPN shBeta3 
pSTAT3 (Tyr 705) • I -
actin 
Figure 26. Impaired STAT3 signaling in SUM159 shPN and sh8eta3 cells. 
Western blot analysis of STAT3 phosphorylation (tyrosine 705) in the indicated 
SUM159 cell lines. Protein was isolated from cells grown in serum-reduced 
media (0.1% serum) for 48 hours. 
102 
shGFP shPN shBeta3 
Conditioned Media mock +shGFP +shPN mock +shGFP +shPN mock +shGFP +shPN 
60' 
pSTAT3 
total STAT3 
actin 
Figure 27. Rescue of STAT3 signaling with conditioned media. The 
indicated SUM159 cell lines (shGFP, shPN and shBeta3) were grown in serum-
reduced media (0 .1% serum) for 48 hours. The cells were then transiently 
exposed (60 minutes) to media conditioned from shGFP or shPN cells; 0.1% 
media served as a mock control. Western blot analysis shows the levels of 
phosphorylated STAT3 (tyrosine 705) , total STAT3 and actin. 
Inhibition of the ERK pathway impairs cytokine transcription 
Next we wished to determine the proximal signals downstream of the 
periostin-integrin J33 pathway that are responsible for controlling production of the 
cytokines. As NF-KB signaling is known to regulate the transcription of numerous 
cytokines, including IL6 and IL8320 , this seemed like a logical place to start. 
Further, periostin has been reported to activate this pathway in the context of 
chronic inflammation 161 . No changes were observed in the level of active, 
phosphorylated p65 (Figure 28A), an NF-KB transcription factor327 . This 
suggests that the NF-KB pathway is not altered , in this context, in cells with 
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knockdown of periostin or integrin 133. In further support of this notion , SUM159 
shGFP, shPN and shBeta3 cells were equally responsive to tumor necrosis 
factor alpha (TN F-a) stimulation (Figure 288). 
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Figure 28. The NF-KB pathway is intact in SUM159 knockdown cells. A. The 
indicated SUM159 cells were grown in serum-reduced media (0.1% serum) for 
24 hours prior to protein isolation. Western blot analysis shows the levels of 
phosphorylated p65 (serine 536) and actin. B. The indicated SUM159 cells were 
grown in serum reduced media for 24 hours and treated with TN F-a (1 0 ng/ml) 
for 5 minutes. Western blot analysis shows the levels of phosphorylated p65 
(serine 536) , total p65 and actin . 
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However, using Ingenuity Pathway Analysis (IPA) software, we noted that , 
in comparison to SUM159 shGFP cells , cells with knockdown of periostin (shPN) 
exhibited significant activation of an expression profile that is characteristic of 
cells treated with two ERK pathway inhibitors (Figure 29A and 298) . This 
suggested that cells with disrupted periostin signaling might display impaired 
activation of the ERK pathway. Indeed, cells with knockdown of periostin or 
integrin 133 were found to have dramatically reduced levels of phosphorylated , 
active ERK1/2 (Figure 30) . 
A. B. 
Figure 29. IPA identifies an ERK signaling defect in SUM159 shPN cells. A. 
IPA analysis of genes differentially expressed in SUM159 shPN , compared to 
shGFP cells , shows that shPN cells exhibit significant activation of a gene 
expression profile characteristic of cells treated with an ERK pathway inhibitor, 
PD98059 (score +4.087, P = 1.58 x 10-8) . B. Same as in A but shows a gene 
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expression profile characteristic of cells treated with another ERK pathway 
inhibitor, U0126 (score +2.391 , P = 2.29 x 10-8). Red shapes indicate expression 
is increased relative to shGFP cells while green shapes indicate repression . 
Blue lines are consistent with predicted repression in response to the inhibitor 
and orange lines are consistent with predicated induction . Yellow lines depict 
inconsistent changes while gray lines represent neutral/unknown changes. 
shGFP shPN shBeta3 
pERK1/2 
total ERK1/2 
Figure 30. Knockdown of periostin or integrin 133 impairs ERK signaling. 
The indicated SUM159 cell lines were grown in serum-reduced media (0.1% 
serum) for 24 hours prior to protein isolation. Western blot analysis shows the 
levels of phosphorylated ERK1/2 (threonine 202/tyrosine 204) and actin . 
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To test whether this inhibition of the ERK signaling pathway in SUM 159 
shPN and shBeta3 cells could be responsible for the impaired cytokine 
production in the these cells , we treated SUM159 shGFP cells with two ERK 
pathway inhibitors (PD184352 and U0126) . Pharmacologic inhibition of ERK 
signaling resulted in a significant reduction in the mRNA levels of both IL6 and 
ILB (Figure 31A and 31 8), suggesting that activation of the ERK pathway lies 
upstream of cytokine production in SUM159 cells. 
A. 
1.2 
c: 
.2 
(/) 0.8 (/) 
Ill 
... 
c. 
)( 0.6 w 
Q) 
> 
... 0.4 nl 
a; 
a: 
0.2 
0 
o shGFP +mock 
• shGFP +PD184352 
** 
** 
IL-6 IL-8 
B. 
1.2 
g 1 -
u; 
(/) 
Q) 
e. 0 .8 
w 
Q) 
~ 0.6 
nl 
a; 
a: 0.4 
0.2 
0 
o shGFP +mock 
•shGFP +U0126 
IL-6 IL-8 
Figure 31. Inhibition of the ERK pathway reduces IL6 and ILB transcription. 
A. SUM159 shGFP cells were treated with DMSO (mock) or PD184352 (1 0 1-1M) 
for 24 hours prior to RNA isolation. IL6 and ILB expression levels were 
measured by qRT-PCR. B. SUM159 shGFP cells were treated with DMSO 
(mock) or U0126 (25 1-JM) for 24 hours prior to RNA isolation. /L6 and ILB 
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expression levels were measured by qRT-PCR. ** P < 0.01 , error bars represent 
SEM. 
Knockdown of periostin in Hs578T cells 
To test whether the connection between periostin , cancer stem cells and 
cytokine signaling is applicable outside of the SUM159 line, we used Hs578T 
cells , another basal-like breast cancer cell line249 , and stably expressed a control 
shRNA (shGFP), or one directed at periostin (shPN). Successful knockdown 
was confirmed at the RNA and protein level (Figure 32A) . Consistent with our 
previous observations, Hs578T cells with knockdown of periostin generated 
significantly fewer mammospheres (Figure 328) . Moreover, there was also a 3-
fold reduction in the ALDH-positive subpopulation (Figure 32C). The loss of 
these cancer stem cell characteristics in Hs578T shPN cells was associated with 
reduced activation of the STAT3 pathway (Figure 320). Given that periostin 
knockdown resulted in similar phenotypic changes in Hs578T cells, this indicates 
that the functional relevance of periostin regulated signaling pathways to breast 
cancer stem cells may be more broadly applicable. 
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Figure 32. Periostin regulates cancer stem cell phenotypes in Hs578T 
cells. A. qRT-PCR of periostin levels in control (shGFP) and knockdown (shPN) 
cells. Inset shows western blot analysis for periostin in the conditioned media of 
the same cells . B. Control (shGFP) or knockdown (shPN) Hs578T cells were 
grown as mammospheres and quantified. The data represent three independent 
experiments each with an n=3. C. The fold change in the percentage of ALDH-
positive cell population was determined using the ALDEFLUOR assay. The 
indicated Hs578T cells were grown in serum-reduced media (0.1% serum) for 48 
hours prior to analysis. The data represent three independent experiments. D. 
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Western blot analysis of STAT3 phosphorylation (tyrosine 705) in the indicated 
Hs578T cell lines. Protein was isolated from cells grown in serum-reduced 
media (0.1% serum) for 48 hours. * P < 0.05, ** P < 0.01, error bars represent 
SEM. 
Periostin regulates the transcription of Wnt ligands in Mill cells 
While periostin knockdown in Mill cells significantly reduced 
mammosphere formation, it did not have an appreciable effect on either the 
ALDH-positive subpopulation or cytokine production. Therefore, we sought to 
identify pathways downstream of periostin that could regulate mammosphere 
formation in Mill cells. Using qRT-PCR to screen for the expression of numerous 
components of the Wnt, Notch and Hedgehog pathways, we found that periostin 
was required for the transcription of two Wnt ligands, WNT1 and WNT3A; this 
was correlated with reduced activation of Wnt signaling, as assessed by 
transcription of the Wnt target gene AXIN2 (Figure 33) . 
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Figure 33. Knockdown of periostin in Mill cells impairs the transcription of 
WNT ligands and activation of Wnt signaling. qRT-PCR was used to 
measure the levels of WNT1, WNT3A and AXIN2 mRNA in control (shGFP) and 
knockdown (shPN) cells . RNA was isolated from cell grown in serum-reduced 
media (0.1% serum) for 48 hours. ** P < 0.01 , error bars represent SEM. 
Similar defects in the transcription of WNT ligands and activation of 
downstream signaling were noted when these cells were grown as 
mammospheres. Whereas Mill shGFP cells cultivated as mammospheres 
expressed 12.8-fold more WNT1 and 27-fold more AXIN2 than cells grown in 
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adherent conditions, this response was remarkably blunted in Mill shPN cells 
(Figure 34A and 348). This suggests that the expression of periostin is 
necessary for activation of the Wnt signaling pathway that occurs during 
mammosphere formation . 
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Figure 34. Periostin expression is required for the induction of Wnt 
signaling during mammosphere growth. A. RNA was isolated from Mill 
shGFP and shPN cells that were grown either under standard adherent 
conditions or as mammospheres and qRT-PCR was used to assess the 
expression of WNT1. B. Same as in A, except qRT-PCR was used to assess the 
expression of AXIN2. * P < 0.05; ns, not significant; error bars represent SEM. 
Wnt ligands are known to regulate the self-renewal of normal and 
malignant stem cells294 ·297 . Therefore, we wished to test the ability of Mill cells to 
self-renew through serial passage of mammospheres. When Mill shGFP 
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mammospheres were dissociated and grown as secondary spheres there was a 
2.1-fold increase in the number of secondary mammospheres, suggesting an 
expansion of stem-like cancer cells (Figure 35). In contrast, there was a slight 
decrease in the number of secondary spheres formed by Mill shPN cells , 
consistent with the repression of Wnt signaling (Figure 35) . 
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Figure 35. Periostin knockdown impairs secondary mammosphere growth 
of Mill cells. Mill shGFP or shPN primary mammospheres were quantified , 
dissociated and re-seeded as secondary mammospheres. After one week of 
growth the number of secondary mammospheres were quantified . The data for 
primary mammosphere growth is reproduced here from Figure 14A. * P < 0.05, 
error bars represent SEM. 
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Inhibition of the ERK pathway in Mill cells reduces the ALDH-positive 
population 
In SUM159 cells, knockdown of periostin led to a dramatic reduction in the 
ALDH-positive subpopulation of cells that was associated with inhibition of the 
ERK pathway. We hypothesized that this effect was not observed in Mill cells 
because they exhibit constitutive activation of the ERK pathway downstream of 
oncogenic RAS. To test this idea, we treated Mill shGFP cells with a 
pharmacologic inhibitor of the ERK pathway and measured the percentage of 
ALDH-positive cancer cells. Indeed, there was a 2.2-fold decrease in the ALDH 
subpopulation when the ERK pathway was inhibited in Mill shGFP cells (Figure 
36A and 368), implying that activation of the ERK pathway is required to 
maintain the ALDH-positive subpopulation. 
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Figure 36. ERK inhibition reduces the ALDH-positive subpopulation in Mill 
cells. A. Representative ALDH plots of Mill shGFP cells treated with DMSO 
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(mock) or PD184352 for 48 hours. The cells were stained using the 
ALDEFLUOR assay for 30 minutes prior to analysis by flow cytometry. DEAB, 
an inhibitor of ALDH, is used as a gating control. B. Quantification of the fold 
change in the percentage of ALDH-positive cell population after treatment of Mill 
shGFP cells with PD184352 or mock control. The data represent three 
independent experiments. * P < 0.05, error bars represent SEM. 
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DISCUSSION 
As a matricellular ECM protein , periostin can potentially serve as a crucial 
mediator of interactions between cancer cells and their surrounding 
microenvironment by binding other matrix proteins, soluble factors , or through the 
activation of integrin receptors 128 . In breast cancer, periostin is highly 
expressed100•189 and this has been correlated with metastatic progression 177 and 
angiogenesis 197 . There is limited mechanistic detail to how periostin may 
function in breast cancer but it has been published that it can activate integrin 
signaling in endothelial cells to promote angiogenesis 197 and others have 
suggested that it may play a role in EMT105·199. Meanwhile, integrins have come 
to serve as essential markers of mammary epithelial cells and potential 
regulators of cancer stem cells328 . In this chapter we hypothesized that the 
periostin-integrin J33 axis controls downstream signaling that is important in the 
context of cancer stem cell regulation and we sought to identify these pathways. 
We started by profiling gene expression patterns in SUM159 shGFP, 
shPN and shBeta3 cells . This analysis revealed that 1182 genes were 
differentially expressed across the three cell lines. Although we observed 
consistent effects on cancer stem cell phenotypes in SUM159 shPN and shBeta3 
cells , PCA indicated that there were substantial gene expression differences 
between these cells. Such differences are not surprising since the two proteins 
also function in non-redundant signaling pathways. To focus specifically on the 
pathways that were activated downstream of periostin we applied two criteria : 
116 
first, we identified the most highly repressed genes in SUM159 shPN cells 
compared to shGFP cells; second , we filtered this list of genes to include only 
those which are coordinately regulated in shBeta3 cells. Remarkably, this 
analysis identified ALDH1A1 as the top hit. This further substantiates our data 
gathered using the ALDEFLUOR assay, which clearly showed a depletion of 
ALDH-positive cells in SUM159 shPN and shBeta3 cells. However, at present, it 
is not clear whether this results from perturbation of ALDH1A 1 transcription 
downstream of periostin or is a consequence of a reduction in the cell population 
which highly expresses this gene. Given that ALDH1 expression is associated 
with a poor prognosis212 in breast cancer this may be a semantic clinical point, 
however, to fully understand the function of periostin it will be important in clarify 
this issue. Another dehydrogenase, XDH , was also among the ten most 
repressed genes. This enzyme is known to contribute to the generation of 
reactive oxygen species (ROS) and increased ROS production has recently been 
reported to expand a cancer stem cell population in basal-like breast cancers329 . 
The analysis of coordinately repressed genes also identified other 
interesting, and potentially relevant, targets downstream of periostin. The 
second hit was PTGS2 (also known as COX2) , an important enzyme in the 
synthesis of prostaglandin. This is interesting in light of recent reports which 
found that prostaglandin E2, produced by mesenchymal stem cells , can promote 
the formation of breast cancer stem cells330·331. The potential roles of ITGB4 and 
IL 13RA2 in the regulation of cancer stem cells is less clear but ITGB4 was 
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recently demonstrated to be important for the self-renewal of prostate cancer 
stem cells289 and IL 13RA2 is part of a gene expression signature characteristic of 
breast cancer metastasis to lung332 . 
Five of the top ten repressed genes were cytokines, chemokines, or their 
receptors. This observation is in line with the results from GSEA, which found 
that the cytokine pathway was the most significantly repressed gene set in 
SUM159 shPN cells, compared to shGFP cells. Other notable pathways that 
were significantly repressed include the inflammatory pathway, hematopoietic 
cell lineage pathway and local acute inflammation response pathway. Each of 
these pathways are comprised of numerous cytokines and a leading edge 
analysis of these gene sets pinpoint three cytokines - IL 1 A, IL6 and ILB - that 
seem to be the primary drivers of this effect. Other ECM proteins such as 
collagen, laminin and fibronectin can also influence cytokine expression 333 . The 
presence of the hematopoietic lineage and stem cell gene sets are especially 
interesting in light of the fact that periostin has been found to localize to stem cell 
niches in the bone marrow118 , raising the possibility that this may have 
physiologic relevance to hematopoietic stem cells. The loss of cytokine 
expression following perturbation of periostin is consistent with a previous report 
which demonstrated that periostin was required for the production of multiple 
proinflammatory cytokines, including IL-1 a, in the context of chronic skin 
inflammation 161 . Moreover, this response was shown to involve integrin av161 . 
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Our data suggest that a similar program downstream of periostin may be used to 
regulate breast cancer stem cells. 
Consistent with a role for periostin-activated integrin ~3 signaling in the 
regulation of cytokine expression, we found that both IL-6 and IL-8 were also 
repressed in SUM159 shBeta3 cells. Furthermore, knockdown of periostin or 
integrin ~3 resulted in reduced activation of the STAT3 pathway that could be 
rescued by transiently exposing the knockdown cells to media conditioned from 
SUM159 shGFP cells. This supports a model in which cells without an intact 
periostin-integrin ~3 signaling axis have an impaired ability to produce cytokines 
and, therefore, have a corresponding reduction in the activation of STAT3 
signaling. 
This model is compelling because of the rapidly accumulating evidence 
that links IL-6 and IL-8 to breast cancer stem cells. For example, cancer stem 
cells have been found to express high levels of numerous inflammatory genes 
and a signaling network involving IL-6 activation of STAT3 was necessary for 
mammosphere growth322 . A separate study used a large-scale shRNA screen 
and found that /L6 expression was required for the growth of CD44+/CD24- stem-
like cancer cells323 . It was also reported that the cancer stem cell population had 
enhanced STAT3 activation, which was dramatically reduced upon inhibition of 
/L6 expression323 . In SUM159 cells, IL-8 can increase the percentage of ALDH-
positive cells220 while targeting of CXCR1, the IL-8 receptor, reduces the 
percentage of ALDH-positive cells251 , suggesting that IL-8 signaling is especially 
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important for the maintenance of this subpopulation. In line with these ideas, 
combined inhibition of IL-6 and IL-8 impaired the survival and growth of triple-
negative breast cancer cells lines334. Overall, our results also support the 
concept that IL-6 and IL-8, along with downstream activation of the STAT3 
pathway, are important cancer stem cell pathways, as we found them to be 
suppressed in SUM159 shPN and shBeta3 cells that have a depleted cancer 
stem cell population. Similar changes in cancer stem cell traits and STAT3 
signaling were found in another breast cancer cell line, Hs578T, with knockdown 
of periostin, implying that this pathway may be relevant to other breast cancer 
cells. It is worth noting that, in contrast to the studies cited above, we did not 
detect any defect in cell proliferation or increase apoptosis in cells carrying 
knockdown of periostin. This suggests that these cell may rely on alternative 
signaling pathways to sustain cell survival and proliferation; indeed, MYC 
amplification has been noted in SUM159 cells335 and it is possible that this 
genetic alteration could sustain cell proliferation in spite of impaired activation of 
upstream signaling pathways. Furthermore, the signaling changes may be 
understood when considering recent studies that have reported on the cellular 
plasticity that exists between non-cancer stem cells and cancer stem cells325·326 . 
For instance, it has been show that the IL-6-STAT3 pathway can shift this 
equilibrium in favor of cancer stem cells325·336 . Thus, one possibility may be that 
periostin, at least in part through control of cytokine production, is able to 
maintain an equilibrium that favors the cancer stem cell state. 
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There are potential clinical implications that arise from this work. For 
instance, in TNBC cells resistant to chemotherapy it was reported that there is an 
enrichment of stem-like cancer cells with increased activation of the TGF-~ 
pathway and concomitant ILB expression337 . As periostin is a direct TGF-~ target 
gene, it is possible that it could have a role in the IL-8 induced expansion of 
cancer stem cells after chemotherapy. As mentioned previously, it has also been 
shown that inhibition of the IL-8 receptor, CXCR1 , may represent a novel 
approach to targeting breast cancer stem cells251 . As we have linked periostin 
signaling to the production of IL-8, tumors that express an operative periostin-
integrin ~3 signaling axis may be exquisitely sensitive to therapies directed at 
cytokine networks. Additionally, inhibitors of the PI3KimTOR pathway, many of 
which are in clinical trials338 , have been demonstrated to lead to increased IL-8 
production, rendering these cells sensitive to JAK2 inhibitors339 . It will be 
important to see whether periostin signaling could modulate the cellular response 
to inhibitors of P13KimTOR or JAKs. 
Our studies have addressed the role of tumor-cell derived periostin and 
the autocrine networks downstream of this ECM protein. It has been shown that 
periostin 118 and cytokines324 '340 can also be derived from tumor-associated 
stromal cells such as fibrolasts and mesenchymal stem cells . In principle this 
could elicit similar effects in terms of cancer stem cell maintenance, however, it is 
possible that cancer cells competent to secrete their own microenviornmental 
niche may have a growth , survival or self-renewal advantage. For example, 
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breast cancer cells that exhibit high expression of CXCL 1 and CXCL2 are more 
competent to seed lung metastases341. In some cases this has been linked to 
the recruitment of myeloid cells342 but it might also be related to activation of 
autocrine signaling pathways in the tumor cells. It is certainly possible that 
tumor-derived factors , especially insoluble matrix proteins, could exert a more 
potent effect when produced locally. 
We also sought to identify the intracellular signaling pathways activated 
downstream of periostin-integrin ~3 that may act to control the production of 
cytokines. Ingenuity Pathway Analysis clearly indicated that the differentially 
expressed genes in SUM159 shPN cells, compared to shGFP cells, significantly 
overlapped with those genes known to change when cells are treated with 
various ERK pathway inhibitors. Western blot analysis of phosphorylated 
ERK1/2 indicates that SUM159 shPN cells , as well as shBeta3 cells , do indeed 
have reduced activation of this signaling pathway. This is consistent with studies 
in periodontal ligament cells that found evidence to suggest that periostin 
activated the ERK pathway through integrin av~3155 . Moreover, Src-homology 2 
domain-containing phosphatase (SHP2) can promote the maintenance of breast 
cancer stem cells through activation of the ERK pathwal43 , suggesting that ERK 
signaling may be particularly important to this highly malignant subpopulation . 
This is supported by the finding that pharmacologic inhibition of the ERK pathway 
resulted in reduced transcription of /L-6 and /L-8 , two cytokines that, as outlined 
above, are critical to breast cancer stem cells. Given that the NF-KB pathway is 
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a well-characterized regulator of cytokine transcription319 , which may be activated 
by periostin 161 , we were surprised to find that knockdown of periostin or integrin 
133 had no apparent effect on the responsiveness of these cells to stimulation of 
NF-KB signaling. The reason for this discrepancy is not known, but it is entirely 
possible that it relates to various oncogenic lesions that were not present in the 
untransformed cells where periostin stimulation of NF-KB signaling was first 
described161 . 
Finally, we tried to understand the pathways controlled by periostin in Mill 
cells, where we first identified it as a potential regulator of cancer stem cell 
maintenance. Since cytokine transcription was evidently downstream of ERK 
signaling in SUM159 cells, we hypothesized that because Mill cells overexpress 
oncogenic RAS, periostin knockdown might alter different downstream pathways. 
In screening various signaling pathways known to control breast cancer stem 
cells we found that Mill shPN cells showed dramatic suppression of WNT1 and 
WNT3A transcription , suggesting that periostin may control the transcription of 
WNT ligands. This is in contrast, but by no means in conflict, with the previously 
described role for periostin in binding extracellular Wnt ligands and, thereby, 
ostensibly enhancing their presentation to cancer cells 118 . It is also notable 
because the regulation of WNT ligand transcription is poorly understood. Our 
data suggest that ECM proteins could play a role in this process, but the proximal 
signals activated downstream of periostin in Mill cells remain unclear. 
Importantly, impaired activation the Wnt pathway was associated with a defect in 
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the self-renewal of stem-like cancer cells, as assessed by serial passage of Mill 
mammospheres. This finding is in agreement with the notion that WNTs can act 
to promote the self-renewal of mammary stem cells294 and implies that similar 
pathways may be utilized by cancer stem cells. Interestingly, while periostin 
knockdown did not change the percentage of Mill cells that were ALDH-positive , 
inhibition of ERK pathway did. In combination with the data obtained in the 
SUM159 cell line, this finding suggests a dichotomy wherein the Wnt pathway is 
crucial to the regulation of mammosphere-forming cells , while activation of the 
ERK pathway is more important to the ALDH-positive subpopulation . However, 
whether there are any functional differences between these two cellular 
populations remains an open question . 
Based on the studies presented in this dissertation , we propose the 
following working model to describe the function of periostin signaling in breast 
cancer stem cells (Figure 37) . In this model , cells co-expressing periostin and 
integrin av~3 are able to activate ERK signaling to control autocrine production of 
the cytokines IL-6 and IL-8. In different cellular contexts, periostin may regulate 
the transcription of WNT ligands, although the upstream signals responsible for 
this are unknown at present. In both cases , these secreted factors can act to 
promote the maintenance of breast cancer stem cells. As previously reported 118 , 
periostin can also physically interact with WNTs to regulate breast cancer stem 
cells. Because integrin ~3 is a marker of luminal progenitors, the presumed cell 
of origin for basal-like like breast cancers, we suggest that this signaling network 
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is most likely to be operative in this molecular subtype, when cancer cells gain 
the ability to secrete periostin. In this scenario, the implication is that basal-like 
breasts can establish a microenvironmental niche supportive of breast cancer 
stem cells . 
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Figure 37. Working model of periostin-integrin avJ33 signaling in breast 
cancer stem cells. 
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FUTURE DIRECTIONS 
The results presented in this dissertation give rise to numerous questions 
that could be experimentally addressed in the future. For example: 
1. Is periostin able to induce entry into a cancer stem cell state? 
Our knockdown experiments have only addressed the role of periostin in 
cancer stem-like cells that have already acquired high expression of periostin 
and integrin ~3. It will be necessary to test the effect of ectopic expression of 
periostin in cells that do not exhibit cancer stem characteristics (for example, the 
Mil cell line). This could be accomplished by cloning periostin eDNA into 
expression vectors and establishing stable cell lines through retroviral 
transduction. It will be important to consider the specific isoform of periostin that 
will be overexpressed and whether the cell line has expression of integrin av~3 ; if 
not, double-stable cell lines could be established that also overexpress integrin 
~3. which has been shown to increase surface levels of the functional integrin 
complex344 . These experiments will help to clarify whether periostin is primarily a 
maintenance factor or if can actively drive the formation of stem-like cancer cells. 
2. Can periostin serve as a biomarker for basal-like breast cancers? 
The data we generated using in silica Kaplan-Meier analysis indicated that 
high periostin expression is associated with reduced relapse-free survival in ER-
negative cancers, the majority of which are likely to fall under the basal-like 
molecular classification. Furthermore, our working model postulates that a 
periostin-integrin av~3 signaling axis is most likely to be active in a subset of 
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basal-like cancers, where it could maintain a population of cancer stem cells. 
These findings are line with another study that reported periostin expression is 
associated with higher cancer stem cell numbers and a worse clinical 
outcome266 . These initial observations should be expanded on, ideally in cohorts 
of patients where the molecular subtype of the tumors has been determined . 
One prediction would be that high periostin expression might be an independent 
prognostic factor for metastatic progression or resistance to chemotherapy, two 
processes that may be driven by cancer stem cells. Another possibility would be 
to incorporate periostin as a biomarker in early-phase clinical trials that are 
designed to target cancer stem cells. 
3. What is the role of periostin in resistance to chemotherapy and 
metastasis? 
Cancer stem cells are predicted to underlie resistance to chemotherapy 
and metastasis. Since we and others118 have found that periostin is a regulator 
of cancer stem cell maintenance it is reasonable to speculate that it could also be 
involved in these two clinically important processes. Control or periostin 
knockdown cells could be used in high-throughput screening assays to test 
whether, as one would predict, loss of periostin could sensitize cancer cells to 
various chemotherapeutic agents that are commonly used in the clinic. 
Alternatively, a similar approach could be employed to screen agents designed to 
target cancer stem cells; in this case cells with high periostin expression might be 
more sensitive to such therapies. In vivo metastasis assays using the 
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bioluminescent SUM159 cells could be performed to test for an effect on 
metastasis. As periostin can be derived from lung fibroblasts 118 it is possible that 
knockdown of periostin in tumor cells may not have an appreciable effect. On 
the other hand, serum periostin levels are associated with bone metastasis in 
human breast cancer. One could formally test the role of tumor cell-derived 
periostin in bone metastasis by intracardiac injection of the bioluminescent cells 
described above. 
4. What is the function of periostin in normal stem cell niches? 
Periostin expression has been detected in normal stem cell niches in the 
breast, bone, intestine and skin 118 . Data presented here, and by others 118 , 
shows that periostin can alter known regulators of stem cells, including those of 
Wnt and cytokine pathway. Therefore, it is possible that periostin may have 
functional roles in adult stem cells. It is worth noting that multiple periostin 
knockout mouse models have been generated 117"118·135 and in each case the 
mice were viable and had modest phenotypes. It is possible that there are 
redundant ECM molecules but it would be worth examining the stem cell 
compartments of these mice in more detail. This is especially true of the bone 
niche, as hematopoietic stem cells are controlled in large part by cytokines and 
because we found this pathway, along with the hematopoietic lineage and stem 
pathway, to be suppressed in cells with knockdown of periostin. It could also be 
worth generating conditional knockout mice using inducible or tissue-specific 
Cre-Lox systems. 
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GENERAL CONCLUSIONS 
In summary, the findings presented in this dissertation provide support to 
the idea that tumor cell-derived periostin , through activation of integrin signaling , 
is an important regulator of breast cancer stem cells. We found that an autocrine 
periostin-integrin ~3 signaling axis was intact, and potentially operative, in a 
subset of basal-like breast cancer cells . Furthermore, periostin expression was 
associated with a poor prognosis in patients with ER-negative cancers, many of 
which represent basal-like cases. Components of this signaling axis were 
required for the maintenance of numerous cancer stem cell traits and periostin 
served to control the production of other secreted regulators of cancer stem cells 
including a distinct cytokine network and multiple WNT ligands. Thus we have 
established a link between autocrine ECM production , integrin signaling and the 
activation of downstream pathways that are crucial regulators of breast cancer 
stem cells. Collectively, these results suggest that basal-like breast cancers can 
establish a microenvironemntal niche supportive of cancer stem cells , which 
might be relevant as a biomarker or therapeutic target. 
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